US20040242566A1 - Dipeptidyl peptidase inhibitors - Google Patents

Dipeptidyl peptidase inhibitors Download PDF

Info

Publication number
US20040242566A1
US20040242566A1 US10/809,638 US80963804A US2004242566A1 US 20040242566 A1 US20040242566 A1 US 20040242566A1 US 80963804 A US80963804 A US 80963804A US 2004242566 A1 US2004242566 A1 US 2004242566A1
Authority
US
United States
Prior art keywords
phenyl
group
alkyl
substituted
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/809,638
Other languages
English (en)
Inventor
Jun Feng
Stephen Gwaltney
Stephen Kaldor
Jeffrey Stafford
Michael Wallace
Zhiyuan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SYNX Inc
Takeda Pharmaceutical Co Ltd
Qualcomm Inc
Takeda California Inc
Original Assignee
Syrrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syrrx Inc filed Critical Syrrx Inc
Priority to US10/809,638 priority Critical patent/US20040242566A1/en
Assigned to SYNX, INC. reassignment SYNX, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FENG, JUN, ZHANG, ZHIYUAN, STAFFORD, JEFFREY A., GWALTNEY, STEPHEN L., KALDOR, STEPHEN W., WALLACE, MICHAEL B.
Assigned to QUALCOMM, INCORPORATED reassignment QUALCOMM, INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ARGAWAL, AVNEESH, NAGUIB, AYMAN FAWAY, SUTIVONG, ARAK
Publication of US20040242566A1 publication Critical patent/US20040242566A1/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TAKEDA SAN DIEGO, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the invention relates to compounds that may be used to inhibit dipeptidyl peptidases as well as compositions of matter and kits comprising these compounds.
  • the present invention also relates to methods for inhibiting dipeptidyl peptidases as well as treatment methods using compounds according to the present invention.
  • Dipeptidyl Peptidase IV (IUBMB Enzyme Nomenclature EC.3.4.14.5) is a type II membrane protein that has been referred to in the literature by a wide a variety of names including DPP4, DP4, DAP-IV, FAPP, adenosine deaminase complexing protein 2, adenosine deaminase binding protein (ADAbp), dipeptidyl aminopeptidase wV; Xaa-Pro-dipeptidyl-aminopeptidase; Gly-Pro naphthylamidase; postproline dipeptidyl aminopeptidase IV; lymphocyte antigen CD26; glycoprotein GP10; dipeptidyl peptidase IV; glycylproline aminopeptidase; glycylproline aminopeptidase; X-prolyl dipeptidyl aminopeptidase; pep X; leukocyte antigen CD26; glyc
  • DPP-IV is a non-classical serine aminodipeptidase that removes Xaa-Pro dipeptides from the amino terminus (N-terminus) of polypeptides and proteins. DPP-IV dependent slow release of dipeptides of the type X-Gly or X-Ser has also been reported for some naturally occurring peptides.
  • DPP-IV is constitutively expressed on epithelial and endothelial cells of a variety of different tissues (intestine, liver, lung, kidney and placenta), and is also found in body fluids. DPP-IV is also expressed on circulating T-lymphocytes and has been shown to be synonymous with the cell-surface antigen, CD-26. DPP-IV has been implicated in a number of disease states, some of which are discussed below.
  • DPP-IV is responsible for the metabolic cleavage of certain endogenous peptides (GLP-1 (7-36), glucagon) in vivo and has demonstrated proteolytic activity against a variety of other peptides (GHRH, NPY, GLP-2, VIP) in vitro.
  • GLP-1 (7-36) is a 29 amino-acid peptide derived by post-translational processing of proglucagon in the small intestine.
  • DPP-IV has been shown to be the primary degrading enzyme of GLP-1 (7-36) in vivo.
  • GLP-1 (7-36) is degraded by DPP-IV efficiently to GLP-1 (9-36), which has been speculated to act as a physiological antagonist to GLP-1 (7-36).
  • Inhibiting DPP-IV in vivo is therefore believed to be useful for potentiating endogenous levels of GLP-1 (7-36) and attenuating the formation of its antagonist GLP-1 (9-36).
  • DPP-IV inhibitors are believed to be useful agents for the prevention, delay of progression, and/or treatment of conditions mediated by DPP-IV, in particular diabetes and more particularly, type 2 diabetes mellitus, diabetic dislipidemia, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose (IFG), metabolic acidosis, ketosis, appetite regulation and obesity.
  • diabetes in particular diabetes and more particularly, type 2 diabetes mellitus, diabetic dislipidemia, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose (IFG), metabolic acidosis, ketosis, appetite regulation and obesity.
  • ITT impaired glucose tolerance
  • IGF impaired fasting plasma glucose
  • metabolic acidosis ketosis
  • ketosis ketosis
  • appetite regulation and obesity are believed to be useful agents for the prevention, delay of progression, and/or treatment of conditions mediated by DPP-IV, in particular diabetes and more particularly, type 2 diabetes mellitus, diabetic dislipidemia, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose
  • DPP-IV expression is increased in T-cells upon mitogenic or antigenic stimulation (Mattem, T., et al., Scand. J. ImmunoL, 1991, 33, 737). It has been reported that inhibitors of DPP-IV and antibodies to DPP-IV suppress the proliferation of mitogen-stimulated and antigen-stimulated T-cells in a dose-dependant manner (Schon, E., et al., Biol. Chem., 1991, 372, 305). Various other functions of T-lymphocytes such as cytokine production, IL-2 mediated cell proliferation and B-cell helper activity have been shown to be dependent on DPP-IV activity (Schon, E., et al., Scand. J.
  • DPP-IV inhibitors based on boroProline, (Flentke, G. R., et al., Proc. Nat. Acad. Sci. USA, 1991, 88, 1556) although unstable, were effective at inhibiting antigen-induced lymphocyte proliferation and IL-2 production in murine CD4+ T-helper cells.
  • Such boronic acid inhibitors have been shown to have an effect in vivo in mice causing suppression of antibody production induced by immune challenge (Kubota, T. et al., Clin. Exp. Immun., 1992, 89, 192).
  • DPP-IV The role of DPP-IV in regulating T lymphocyte activation may also be attributed, in part, to its cell-surface association with the transmembrane phosphatase, CD45. DPP-IV inhibitors or non-active site ligands may possibly disrupt the CD45-DPP-IV association.
  • CD45 is known to be an integral component of the T-cell signaling apparatus. It has been reported that DPP-IV is essential for the penetration and infectivity of HIV-1 and HIV-2 viruses in CD4+ T-cells (Wakselman, M., Nguyen, C., Mazaleyrat, J. -P., Callebaut, C., Krust, B., Hovanessian, A.
  • inhibitors of DPP-IV may be useful immunosuppressants (or cytokine release suppressant drugs) for the treatment of among other things: organ transplant rejection; autoimmune diseases such as inflammatory bowel disease, multiple sclerosis and rheumatoid arthritis; and the treatment of AIDS.
  • lung endothelial cell DPP-IV is an adhesion molecule for lung-metastatic rat breast and prostate carcinoma cells (Johnson, R. C., et al., J. Cell Biol., 1993, 121, 1423). DPP-IV is known to bind to fibronectin and some metastatic tumor cells are known to carry large amounts of fibronectin on their surface. Potent DPP-IV inhibitors may be useful as drugs to prevent metastases of, for example, breast and prostrate tumors to the lungs.
  • DPP-IV inhibitors may be useful as agents to treat dermatological diseases such as psoriasis and lichen planus.
  • DPP-IV inhibitors may also act to suppress sperm motility and therefore act as a male contraceptive agent.
  • DPP-IV inhibitors have been implicated as novel for treatment of infertility, and particularly human female infertility due to Polycystic ovary syndrome (PCOS, Stein-Leventhal syndrome) which is a condition characterized by thickening of the ovarian capsule and formation of multiple follicular cysts. It results in infertility and amenorrhea.
  • PCOS Polycystic ovary syndrome
  • DPP-IV is thought to play a role in the cleavage of various cytokines (stimulating hematopoietic cells), growth factors and neuropeptides.
  • Stimulated hematopoietic cells are useful for the treatment of disorders that are characterized by a reduced number of hematopoietic cells or their precursors in vivo. Such conditions occur frequently in patients who are immunosuppressed, for example, as a consequence of chemotherapy and/or radiation therapy for cancer. It was discovered that inhibitors of dipeptidyl peptidase type IV are useful for stimulating the growth and differentiation of hematopoietic cells in the absence of exogenously added cytokines or other growth factors or stromal cells.
  • DPP-IV in human plasma has been shown to cleave N-terminal Tyr-Ala from growth hormone-releasing factor and cause inactivation of this hormone. Therefore, inhibitors of DPP-IV may be useful in the treatment of short stature due to growth hormone deficiency (Dwarfism) and for promoting GH-dependent tissue growth or re-growth.
  • Dwarfism growth hormone deficiency
  • DPP-IV can also cleave neuropeptides and has been shown to modulate the activity of neuroactive peptides substance P, neuropeptide Y and CLIP (Mentlein, R., Dahms, P., Grandt, D., Kruger, R., Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV, Regul. Pept., 49, 133, 1993; Wetzel, W., Wagner, T., Vogel, D., Demuth, H. -U., Balschun, D., Effects of the CLIP fragment ACTH 20-24 on the duration of REM sleep episodes, Neuropeptides, 31, 41, 1997).
  • DPP-I inhibitors may also be useful agents for the regulation or normalization of neurological disorders.
  • the present invention relates to compounds that have activity for inhibiting DPP-IV. It is noted that these compounds may also have activity for inhibiting other S9 proteases and thus may be used against these other S9 proteases as well as DPP-IV.
  • the present invention also provides compositions, articles of manufacture and kits comprising these compounds.
  • a pharmaceutical composition that comprises a DPP-IV inhibitor according to the present invention as an active ingredient.
  • Pharmaceutical compositions according to the invention may optionally comprise 0.001%-100% of one or more DPP-IV inhibitors of this invention.
  • These pharmaceutical compositions may be administered or coadministered by a wide variety of routes, including for example, orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, or intrathecally.
  • the compositions may also be administered or coadministered in slow release dosage forms.
  • the invention is also directed to kits and other articles of manufacture for treating disease states associated with DPP-IV.
  • a kit comprising a composition comprising at least one DPP-IV inhibitor of the present invention in combination with instructions.
  • the instructions may indicate the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition.
  • the kit may also comprise packaging materials.
  • the packaging material may comprise a container for housing the composition.
  • the kit may also optionally comprise additional components, such as syringes for administration of the composition.
  • the kit may comprise the composition in single or multiple dose forms.
  • an article of manufacture comprises a composition comprising at least one DPP-IV inhibitor of the present invention in combination with packaging materials.
  • the packaging material may comprise a container for housing the composition.
  • the container may optionally comprise a label indicating the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition.
  • the kit may also optionally comprise additional components, such as syringes for administration of the composition.
  • the kit may comprise the composition in single or multiple dose forms.
  • the compounds, compositions, kits and articles of manufacture are used to inhibit DPP-IV.
  • the compounds, compositions, kits and articles of manufacture are used to treat a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state.
  • a compound is administered to a subject wherein DPP-IV activity within the subject is altered, preferably reduced.
  • a prodrug of a compound is administered to a subject that is converted to the compound in vivo where it inhibits DPP-IV.
  • a method of inhibiting DPP-IV comprises contacting DPP-IV with a compound according to the present invention.
  • a method of inhibiting DPP-IV comprises causing a compound according to the present invention to be present in a subject in order to inhibit DPP-IV in vivo.
  • a method of inhibiting DPP-IV comprises administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits DPP-IV in vivo.
  • the compounds of the present invention may be the first or second compounds.
  • a therapeutic method comprises administering a compound according to the present invention.
  • a method of inhibiting cell proliferation comprises contacting a cell with an effective amount of a compound according to the present invention.
  • a method of inhibiting cell proliferation in a patient comprises administering to the patient a therapeutically effective amount of a compound according to the present invention.
  • a method of treating a condition in a patient which is known to be mediated by DPP-IV, or which is known to be treated by DPP-IV inhibitors comprising administering to the patient a therapeutically effective amount of a compound according to the present invention.
  • a method for using a compound according to the present invention in order to manufacture a medicament for use in the treatment of disease state which is known to be mediated by DPP-IV, or which is known to be treated by DPP-IV inhibitors.
  • a method for treating a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state comprising: causing a compound according to the present invention to be present in a subject in a therapeutically effective amount for the disease state.
  • a method for treating a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state comprising: administering a first compound to a subject that is converted in vivo to a second compound such that the second compound is present in the subject in a therapeutically effective amount for the disease state.
  • the compounds of the present invention may be the first or second compounds.
  • a method for treating a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state comprising: administering a compound according to the present invention to a subject such that the compound is present in the subject in a therapeutically effective amount for the disease state.
  • a method for treating a cell proliferative disease state comprising treating cells with a compound according to the present invention in combination with an anti-proliferative agent, wherein the cells are treated with the compound according to the present invention before, at the same time, and/or after the cells are treated with the anti-proliferative agent, referred to herein as combination therapy.
  • combination therapy is intended to cover when agents are administered before or after each other (sequential therapy) as well as when the agents are administered at the same time.
  • diabetes more particular type 2 diabetes mellitus, diabetic dislipidemia, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose (EFG), metabolic acidosis, ketosis, appetite regulation, obesity, immunosuppressants or
  • the present invention is intended to encompass all pharmaceutically acceptable ionized forms (e.g., salts) and solvates (e.g., hydrates) of the compounds, regardless of whether such ionized forms and solvates are specified since it is well known in the art to administer pharmaceutical agents in an ionized or solvated form. It is also noted that unless a particular stereochemistry is specified, recitation of a compound is intended to encompass all possible stereoisomers (e.g., enantiomers or diastereomers depending on the number of chiral centers), independent of whether the compound is present as an individual isomer or a mixture of isomers.
  • pharmaceutically acceptable ionized forms e.g., salts
  • solvates e.g., hydrates
  • prodrugs may also be administered which are altered in vivo and become a compound according to the present invention.
  • the various methods of using the compounds of the present invention are intended, regardless of whether prodrug delivery is specified, to encompass the administration of a prodrug that is converted in vivo to a compound according to the present invention.
  • certain compounds of the present invention may be altered in vivo prior to inhibiting DPP-IV and thus may themselves be prodrugs for another compound.
  • Such prodrugs of another compound may or may not themselves independently have DPP-IV inhibitory activity.
  • FIG. 1 illustrates a ribbon diagram overview of the structure of DPP-IV, highlighting the secondary structural elements of the protein.
  • FIG. 2 depicts different, representative 5 membered ring structures that may be formed when R 3 and R 4 are taken together to form a substituted or unsubstituted ring.
  • FIG. 3 depicts different, representative 6 membered ring structures that may be formed when R 3 and R 4 are taken together to form a substituted or unsubstituted ring.
  • FIG. 4 depict additional representative 5 or 6 membered ring structures that may be formed when R 3 and R 4 are taken together to form a substituted or unsubstituted ring.
  • Alicyclic means a moiety comprising a non-aromatic ring structure. Alicyclic moieties may be saturated or partially unsaturated with one, two or more double or triple bonds. Alicyclic moieties may also optionally comprise heteroatoms such as nitrogen, oxygen and sulfur. The nitrogen atoms can be optionally quaternerized or oxidized and the sulfur atoms can be optionally oxidized.
  • alicyclic moieties include, but are not limited to moieties with C 3 - C 8 rings such as cyclopropyl, cyclohexane, cyclopentane, cyclopentene, cyclopentadiene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptene, cycloheptadiene, cyclooctane, cyclooctene, and cyclooctadiene.
  • C 3 - C 8 rings such as cyclopropyl, cyclohexane, cyclopentane, cyclopentene, cyclopentadiene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptene, cycloheptadiene, cyclooctane, cyclooctene
  • Aliphatic means a moiety characterized by a straight or branched chain arrangement of constituent carbon atoms and may be saturated or partially unsaturated with one, two or more double or triple bonds.
  • Alkenyl represented by itself means a straight or branched, unsaturated, aliphatic radical having a chain of carbon atoms having at least one double bond between adjacent carbon atoms.
  • C X alkenyl and C X-Y alkenyl are typically used where X and Y indicate the number of carbon atoms in the chain.
  • C 2-6 alkenyl includes alkenyls that have a chain of between 2 and 6 carbons.
  • Alkoxy means an oxygen moiety having a further alkyl substituent.
  • the alkoxy groups of the present invention can be optionally substituted.
  • Alkyl represented by itself means a straight or branched, saturated or unsaturated, aliphatic radical having a chain of carbon atoms, optionally with oxygen (See “oxaalkyl”) or nitrogen atoms (See “aminoalkyl” between the carbon atoms.
  • oxaalkyl oxygen
  • nitrogen atoms See “aminoalkyl” between the carbon atoms.
  • C X alkyl and C X-Y alkyl are typically used where X and Y indicate the number of carbon atoms in the chain.
  • C 1 ⁇ alkyl includes alkyls that have a chain of between 1 and 6 carbons (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylallyl, ethynyl, 1-propynyl, 2-propynyl, and the like).
  • 1 and 6 carbons e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylallyl, ethynyl, 1-propynyl, 2-
  • Alkyl represented along with another radical means a straight or branched, saturated or unsaturated aliphatic divalent radical having the number of atoms indicated or when no atoms are indicated means a bond (e.g., (C 6-10 )aryl(C 1-3 )alkyl includes, benzyl, phenethyl, 1-phenylethyl, 3-phenylpropyl, 2-thienylmethyl, 2-pyridinylmethyl and the like).
  • Alkylene unless indicated otherwise, means a straight or branched, saturated or unsaturated, aliphatic, divalent radical.
  • C X alkylene and C X-Y alkylene are typically used where X and Y indicate the number of carbon atoms in the chain.
  • Alkylidene means a straight or branched saturated or unsaturated, aliphatic radical connected to the parent molecule by a double bond.
  • C X alkylidene and C X-Y alkylidene are typically used where X and Y indicate the number of carbon atoms in the chain.
  • Alkynyl represented by itself means a straight or branched, unsaturated, aliphatic radical having a chain of carbon atoms having at least one triple bond between adjacent carbon atoms.
  • C X alkynyl and C X-Y alkynyl are typically used where X and Y indicate the number of carbon atoms in the chain.
  • C 2-6 alkynyl includes alkynyls that have a chain of between 2 and 6 carbons.
  • amino means a nitrogen moiety having two furtier substituents where a hydrogen or carbon atom is attached to the nitrogen.
  • representative amino groups include —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —NHC 1-3 -alkyl, —N(C 1-3 -alkyl) 2 and the like.
  • the compounds of the invention containing amino moieties may include protected derivatives thereof. Suitable protecting groups for amino moieties include acetyl, tert-butoxycarbonyl, benzyloxycarbonyl, and the like.
  • Aminoalkyl means an alkyl, as defined above, except where one or more substituted or unsubstituted nitrogen atoms (—N—) are positioned between carbon atoms of the alkyl.
  • an (C 2-6 ) aminoalkyl refers to a chain comprising between 2 and 6 carbons and one or more nitrogen atoms positioned between the carbon atoms.
  • Animal includes humans, non-human mammals (e.g., dogs, cats, rabbits;cattle, horses, sheep, goats, swine, deer, and the like) and non-mammals (e.g., birds, and the like).
  • non-human mammals e.g., dogs, cats, rabbits;cattle, horses, sheep, goats, swine, deer, and the like
  • non-mammals e.g., birds, and the like.
  • “Aromatic” means a moiety wherein the constituent atoms make up an unsaturated ring system, all atoms in the ring system are sp hybridized and the total number of pi electrons is equal to 4n+2.
  • An aromatic ring may be such that the ring atoms are only carbon atoms or may include carbon and non-carbon atoms (see Heteroaryl).
  • Aryl means a monocyclic or polycyclic ring assembly wherein each ring is aromatic or when fused with one or more rings forms an aromatic ring assembly. If one or more ring atoms is not carbon (e.g., N, S), the aryl is a heteroaryl. C X aryl and C X-Y aryl are typically used where X and Y indicate the number of atoms in the ring.
  • Aryloxy means an oxygen moiety having a further aryl substituent.
  • the aryloxy groups of the present invention can be optionally substituted.
  • Bicycloalkyl means a saturated or partially unsaturated fused bicyclic or bridged polycyclic ring assembly.
  • Bicycloaryl means a bicyclic ring assembly wherein the rings are linked by a single bond or fused and at least one of the rings comprising the assembly is aromatic.
  • C X bicycloaryl and C X-Y bicycloaryl are typically used where X and Y indicate the number of carbon atoms in the bicyclic ring assembly and directly attached to the ring.
  • “Bridging ring” as used herein refers to a ring that is bonded to another ring to form a compound having a bicyclic structure where two ring atoms that are common to both rings are not directly bound to each other.
  • Non-exclusive examples of common compounds having a bridging ring include borneol, norbornane,7-oxabicyclo[2.2.1]heptane, and the like.
  • One or both rings of the bicyclic system may also comprise heteroatoms.
  • Carbamoyl means the radical —OC(O)NR a R b where R a and R b are each independently two further substituents where a hydrogen or carbon atom is attached to the nitrogen.
  • Carbocycle means a ring consisting of carbon atoms.
  • Carbocyclic ketone derivative means a carbocyclic derivative wherein the ring contains a —CO— moiety.
  • Carbonyl means the radical —CO—. It is noted that the carbonyl radical may be further substituted with a variety of substituents to form different carbonyl groups including acids, acid halides, aldehydes, amides, esters, and ketones.
  • Carboxy means the radical —O 2 —. It is noted that compounds of the invention containing carboxy moieties may include protected derivatives thereof, i.e., where the oxygen is substituted with a protecting group. Suitable protecting groups for carboxy moieties include benzyl, tert-butyl, and the like.
  • Cyano means the radical —CN.
  • Cycloalkyl means a non-aromatic, saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly.
  • C X cycloalkyl and C X-Y cycloalkyl are typically used where X and Y indicate the number of carbon atoms in the ring assembly.
  • C 3-10 cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,5-cyclohexadienyl, bicyclo[2.2.2]octyl, adamantan-1-yl, decahydronaphthyl, oxocyclohexyl, dioxocyclohexyl, thiocyclohexyl, 2-oxobicyclo[2.2.1]hept-1-yl, and the like.
  • Cycloalkylene means a divalent saturated or partially unsaturated, monocyclic or polycyclic ring assembly.
  • C X cycloalkylene and C X-Y cycloalkylene are typically used where X and Y indicate the number of carbon atoms in the ring assembly.
  • Disease specifically includes any unhealthy condition of an animal or part thereof and includes an unhealthy condition that may be caused by, or incident to, medical or veterinary therapy applied to that animal, i.e., the “side effects” of such therapy.
  • fused ring refers to a ring that is bonded to another ring to form a compound having a bicyclic structure where the ring atoms that are common to both rings are directly bound to each other.
  • Non-exclusive examples of common fused rings include decalin, naphthalene, anthracene, phenanthrene, indole, furan, benzofuran, quinoline, and the like.
  • Compounds having fused ring systems may be saturated, partially saturated, carbocyclics, heterocyclics, aromatics, heteroaromatics, and the like.
  • Halo means fluoro, chloro, bromo or iodo.
  • Halo-substituted alkyl as an isolated group or part of a larger group, means “alkyl” substituted by one or more “halo” atoms, as such terms are defined in this Application.
  • Halo-substituted alkyl includes haloalkyl, dihaloalkyl, trihaloalkyl, perhaloalkyl and the like (e.g.
  • halo-substituted (C 1-3 )alkyl includes chloromethyl, dichloromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, perfluoroethyl, 2,2,2-trifluoro-1,1,-dichloroethyl, and the like).
  • Heteroaryl means a cyclic aromatic group having five or six ring atoms, wherein at least one ring atom is a heteroatom and the remaining ring atoms are carbon.
  • the nitrogen atoms can be optionally quaternerized and the sulfur atoms can be optionally oxidized.
  • Heteroaryl groups of this invention include, but are not limited to, those derived from furan, imidazole, isothiazole, isoxazole, oxadiazole, oxazole, 1,2,3-oxadiazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrroline, thiazole, 1,3,4-thiadiazole, triazole and tetrazole.
  • Heteroaryl also includes, but is not limited to, bicyclic or tricyclic rings, wherein the heteroaryl ring is fused to one or two rings independently selected from the group consisting of an aryl ring, a cycloalkyl ring, a cycloalkenyl ring, and another monocyclic heteroaryl or heterocycloalkyl ring.
  • bicyclic or tricyclic heteroaryls include, but are not limited to, those derived from benzo[b]furan, benzo[b]thiophene, benzimidazole, imidazo[4,5-c]pyridine, quinazoline, thieno[2,3-c]pyridine, thieno[3,2-b]pyridine, thieno[2,3-b]pyridine, indolizine, imidazo[ 1 ,2a]pyridine, quinoline, isoquinoline, phthalazine, quinoxaline, naphthyridine, quinolizine, indole, isoindole, indazole, indoline, benzoxazole, benzopyrazole, benzothiazole, imidazo[1,5-a]pyridine, pyrazolo[1,5-a]pyridine, imidazo[1,2-a]pyrimidine, imidazo[1,2-c]pyrimidine, imidazo[1,5-a]pyrim
  • the bicyclic or tricyclic heteroaryl rings can be attached to the parent molecule through either the heteroaryl group itself or the aryl, cycloalkyl, cycloalkenyl or heterocycloalkyl group to which it is fused.
  • the heteroaryl groups of this invention can be substituted or unsubstituted.
  • Heteroaryloxy means an oxygen moiety having a further heteroaryl substituent.
  • the heteroaryloxy groups of the present invention can be optionally substituted.
  • Heteroatom refers to an atom that is not a carbon atom. Particular examples of heteroatoms include, but are not limited to nitrogen, oxygen, and sulfur.
  • Heteroatom moiety includes a moiety where the atom by which the moiety is attached is not a carbon.
  • heteroatom moieties include —N ⁇ , —NRC—, —N + (O ⁇ ) ⁇ , —O—, —S— or —S(O) 2 —, wherein R c is further substituent.
  • Heterobicycloalkyl means bicycloalkyl, as defined in this Application, provided that one or more of the atoms within the ring is a heteroatom.
  • hetero(C 9-12 )bicycloalkyl as used in this application includes, but is not limited to, 3-aza-bicyclo[4.1.0]hept-3-yl, 2-aza-bicyclo[3.1.0]hex-2-yl , 3-aza-bicyclo[3.1.0]hex-3-yl, and the like.
  • Heterobicycloaryl means bicycloaryl, as defined in this Application, provided that one or more of the atoms within the ring is a heteroatom.
  • hetero(C 4-10 )bicycloaryl as used in this Application includes, but is not limited to, 2-amino4-oxo-3,4-dihydropteridin-6-yl, tetrahydroisoquinolinyl, and the like.
  • Heterocycloalkyl means cycloalkyl, as defined in this Application, provided that one or more of the atoms forming the ring is a heteroatom selected, independently from N, O, or S.
  • Non-exclusive examples of heterocycloalkyl include piperidyl, 4-morpholyl, 4-piperazinyl, pyrrolidinyl, perhydropyrrolizinyl, 1,4-diazaperhydroepinyl, 1,3-dioxanyl, 1,4-dioxanyl and the like.
  • Heterocycloalkylene means cycloalkylene, as defined in this Application, provided that one or more of the ring member carbon atoms is replaced by a heteroatom.
  • Haldroxy means the radical —OH.
  • Iminoketone derivative means a derivative comprising the moiety -C(NR)-, wherein R comprises a hydrogen or carbon atom attached to the nitrogen.
  • “Isomers” mean any compound having an identical molecular formulae but differing in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereomers” and stereoisomers that are nonsuperimposable mirror images are termed “enantiomers” or sometimes “loptical isomers.” A carbon atom bonded to four nonidentical substituents is termed a “chiral center.” A compound with one chiral center has two enantiomeric forms of opposite chirality.
  • a mixture of the two enantiomeric forms is termed a “racemic mixture.”
  • a compound that has more than one chiral center has 2 n ⁇ 1 enantiomeric pairs, where n is the number of chiral centers.
  • Compounds with more than one chiral center may exist as ether an individual diastereomer or as a mixture of diastereomers, termed a “diastereomeric mixture.”
  • a stereoisomer may be characterized by the absolute configuration of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center.
  • Enantiomers are characterized by the absolute configuration of their chiral centers and described by the R- and S-sequencing rules of Cahn, Ingold and Prelog. Conventions for stereochemical nomenclature, methods for the determination of stereochemistry and the separation of stereoisomers are well known in the art (e.g., see “Advanced Organic Chemistry” , 4th edition, March, Jerry, John Wiley & Sons, New York, 1992).
  • Niro means the radical —NO 2 .
  • Oxaalkyl means an alkyl, as defined above, except where one or more oxygen atoms (—O—) are positioned between carbon atoms of the alkyl.
  • an (C 2-6 )oxaalkyl refers to a chain comprising between 2 and 6 carbons and one or more oxygen atoms positioned between the carbon atoms.
  • Oxoalkyl means an alkyl, further substituted with a carbonyl group.
  • the carbonyl group may be an aldehyde, ketone, ester, amide, acid or acid chloride.
  • “Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary use as well as human pharmaceutical use.
  • “Pharmaceutically acceptable salts” means salts of inhibitors of the present invention which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity.
  • Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with organic acids such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartatic acid, citric acid, benzoic acid, o-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid,
  • Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic or organic bases.
  • Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and calcium hydroxide.
  • Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine and the like.
  • Prodrug means a compound that is convertible in vivo metabolically into an inhibitor according to the present invention.
  • the prodrug itself may or may not also have DPP-IV inhibitory activity.
  • an inhibitor comprising a hydroxy group may be administered as an ester that is converted by hydrolysis in vivo to the hydroxy compound.
  • esters that may be converted in vivo into hydroxy compounds include acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates, quinates, esters of amino acids, and the like.
  • an inhibitor comprising an amine group may be administered as an amide that is converted by hydrolysis in vivo to the amine compound.
  • Protected derivatives means derivatives of inhibitors in which a reactive site or sites are blocked with protecting groups. Protected derivatives are useful in the preparation of inhibitors or in themselves may be active as inhibitors. A comprehensive list of suitable protecting groups can be found in T. W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999.
  • “Substituted or unsubstituted” means that a given moiety may consist of only hydrogen substituents through available valencies (unsubstituted) or may further comprise one or more non-hydrogen substituents through available valencies (substituted) that are not otherwise specified by the name of the given moiety.
  • isopropyl is an example of an ethylene moiety that is substituted by —CH 3 .
  • a non-hydrogen substituent may be any substituent that may be bound to an atom of the given moiety that is specified to be substituted.
  • substituents include, but are not limited to, aldehyde, alicyclic, aliphatic, alkyl, alkylene, alkylidene, amide, amino, aminoalkyl, aromatic, aryl, bicycloalkyl, bicycloaryl, carbamoyl, carbocyclyl, carboxyl, carbonyl group, cycloalkyl, cycloalkylene, ester, halo, heterobicycloalkyl, heterocycloalkylene, heteroaryl, heterobicycloaryl, heterocycloalkyl, oxo, hydroxy, iminoketone, ketone, nitro, oxaalkyl, and oxoalkyl moieties, each of which may optionally also be substituted or unsubstituted.
  • “Sulfinyl” means the radical —SO—. It is noted that the sulfinyl radical may be further substituted with a variety of substituents to form different sulfinyl groups including sulfinic acids, sulfinamides, sulfinyl esters, and sulfoxides.
  • “Sulfonyl” means the radical —SO 2 —. It is noted that the sulfonyl radical may be further substituted with a variety of substituents to form different sulfonyl groups including sulfonic acids, sulfonamides, sulfonate esters, and sulfones.
  • “Therapeutically effective amount” means that amount which, when administered to an animal for treating a disease, is sufficient to effect such treatment for the disease.
  • Thiocarbonyl means the radical —CS—. It is noted that the thiocarbonyl radical may be further substituted with a variety of substituents to form different thiocarbonyl groups including thioacids, thioamides, thioesters, and thioketones.
  • Treatment or “treating” means any administration of a compound of the present invention and includes:
  • a C 1 alkyl indicates that there is one carbon atom but does not indicate what are the substituents on the carbon atom.
  • a C 1 alkyl comprises methyl (ie., —CH 3 ) as well as -R a R b R c where R a , R b , and R a may each independently be hydrogen or any other substituent where the atom attached to the carbon is a heteroatom or cyano.
  • CF 3 , CH 2 OH and CH 2 CN for example, are all C 1 alkyls.
  • the present invention relates to compounds, compositions, kits and articles of manufacture that may be used to inhibit dipeptidyl peptidases IV (referred to herein as DPP-WV).
  • DPP-IV (EC.3.4.14.5 also known as DPP4, DP4, DAP-IV, adenosine deaminase complexing protein 2, adenosine deaminase binding protein (ADAbp) or CD26) is a 766 residue, 240 kDa protein that is a highly specific membrane bound non-classical serine aminodipeptidase.
  • DPP-IV has a serine type mechanism of protease activity, cleaving off dipeptides from the amino-terminus of peptides with proline or alanine at the penultimate position. In addition the slow release of dipeptides of the type X-Gly or X-Ser is reported for some naturally occurring peptides.
  • DPP-IV is constitutively expressed on epithelial and endothelial cells of a variety of different tissues (intestine, liver, lung, kidney and placenta), and is also found in body fluids. DPP-IV is also expressed on circulating T-lymphocytes and has been shown to be synonymous with the cell-surface antigen, CD-26.
  • the wild-type form of full length DPP-IV is described in GenBank Accession Number NM — 001935 (“Dipeptidyl peptidase IV (CD26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2.
  • DPP-WV is a member of the S9 family of serine proteases, more particularly the S9B family.
  • Other members of the S9 family include, but are not limited to:
  • Subfamily S9A Dipeptidyl-peptidase; Oligopeptidase B (EC3.4.21.83); Oligopeptidase B; Prolyl oligopeptidase (EC3.4.21.26);
  • Subfamily S9B Dipeptidyl aminopeptidase A; Dipeptidyl aminopeptidase B Dipeptidyl-peptidase IV (EC3.4.14.5); Dipeptidyl-peptidase V Fibroblast activation protein alpha subunit; Seprase
  • Subfamily S9C Acylaminoacyl-peptidase (EC3.4.19.1)
  • the compounds of the present invention may also possess inhibitory activity for other S9 family members and thus may be used to address disease states associated with these other family members.
  • FIG. 1 illustrates a ribbon diagram overview of the structure of DPP-IV, highlighting secondary structural elements of the protein.
  • DPP-IV is a cylindrical shaped molecule with an approximate height of 70 ⁇ and a diameter of 60 ⁇ .
  • the catalytic triad of DPP-IV (Ser642, Asp720 and His752) is illustrated in the center of the figure by a “ball and stick” representation. This triad of amino acids is located in the peptidase domain or catalytic domain of DPP-IV.
  • the catalytic domain is covalently linked to the ⁇ -propeller domain.
  • the catalytic domain of DPP-IV includes residues 1-67 and 511-778.
  • the catalytic domain of DPP-IV adopts a characteristic ⁇ / ⁇ hydrolase fold.
  • the core of this domain contains an 8-stranded ⁇ -sheet with all strands being parallel except one.
  • the ⁇ -sheet is significantly twisted and is flanked by three ⁇ -helices on one side and five ⁇ -helices on the other.
  • the topology of the ⁇ -strands is 1, 2, ⁇ 1x, 2x and (1x) (J. S. Richardson: The anatomy and taxonomy of protein structure; (1981) Adv. Protein Chem. 269, 15076-15084.).
  • a number of residues were identified that contribute to the shape and charge characteristics of the active site. Knowledge of these residues has been an important contribution to the design of DPP-IV inhibitors of the present invention.
  • DPP-IV inhibitors of the present invention comprise Formula I:
  • Q is selected from the group consisting of CO, SO, SO 2 , or C ⁇ NR 9 ;
  • R 1 is hydrogen or is selected from the group consisting of (C 1-10 )alkyl, (C 3-12 )cycloalkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl, aryl(C 1-10 )alkyl, (C 9-12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (C 1-3 )alkyl, imino (C 1-3 )alkyl, amino, cyano, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstitute
  • R 2 is selected from the group consisting of halo, perhalo( C 1-10 )alkyl, amino, cyano, thio, (C 1-10 )alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (C 1-3 )alkyl, imino (C 1-3 )alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, and a substituted or unsubstituted 4, 5, 6 or 7 membered ring;
  • R 3 and R 4 are taken together to form a substituted or unsubstituted 5 or 6 membered ring;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted.
  • DPP-IV inhibitors of the present invention comprise Formula II:
  • Q is selected from the group consisting of CO, SO, SO 2 , or C ⁇ NR 9 ;
  • J, K, L, and M are each independently selected from the group of moieties where the ring atom is either C or N;
  • R 1 is hydrogen or is selected from the group consisting of (C 1-10 )alkyl, (C 3-12 )cycloalkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl, aryl(C 1-10 )alkyl, (C 9-12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (C 1-3 )alkyl, imino (C 1-3 )alkyl, amino, cyano, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstitute
  • R 2 is selected from the group consisting of halo, perhalo(C 1-10 )alkyl, amino, cyano, thio, (C 1-10 )alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (C 1-3 )alkyl, imino (Cl- 3 )alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, and a substituted or unsubstituted 4, 5, 6 or 7 membered ring; and
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted.
  • DPP-IV inhibitors of the present invention having particular substitution patterns have significantly improved stability in biological assays. Improvement in the stabilities of the compounds in rat liver microsomes, for example, as demonstrated by the increase in the half life of the test compound in microsomal assays, has been demonstrated in particular substitutions of the DPP-IV inhibitors of the present invention.
  • DPP-IV inhibitors comprising the Formula II with substitution at the 6 and/or the 7-positions result in enhanced stability as demonstrated in biological assays.
  • compounds of the Formula II comprise quinazolinones that are substituted at the 6-position, the 7-position, or both the 6 and 7 positions of the compound of Formula II.
  • Non-limiting examples of the compounds of the Formula II include quinazolinone derivatives, naphthyridine derivatives, 4H-pyrido[3,4-d]pyrimidine derivatives, etc.
  • DPP-IV inhibitors comprise compounds of the Formula II wherein K is CR12, where R12 is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF3, cyano, nitro, alkyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, alkoxy, a carbonyl group, imine group, sulfonyl group and sulfmyl group, each substituted or unsubstituted.
  • R12 is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF3, cyano, nitro, alkyl, aryl, heteroaryl, aminosulfony
  • K is CR12 where R12 is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF3, cyano, nitro, alkyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, alkoxy, a carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, and L is nitrogen.
  • R12 is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF3, cyano, nitro, alkyl, aryl, heteroaryl, aminosulfonyl, alkylsulfon
  • K is CR 12 , where R 12 is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, alkyl, aryloxy, heteroaryloxy, amino, and alkoxy, each substituted or unsubstituted;
  • R 1 is selected from the group consisting of —(CH 2 )-(2-cyano)phenyl, -(CH 2 )-(3-cyano)phenyl, —(CH 2 )-(2-hydroxy)phenyl, —(CH 2 )-(3-hydroxy)phenyl, —(CH 2 )-(2-alkenyl)phenyl, —(CH 2 )-(3-alkenyl)phenyl, —(CH 2 )-(2-alkynyl)phenyl, —(CH 2 )-(3-alkynyl)phenyl, —(CH 2 )-(2-nitro)phenyl, —(CH 2 )-(3-nitro)phenyl, —(CH 2 )-(2-carboxy)phenyl, —(CH 2 )-(3-carboxy)phenyl, —(CH 2 )-(2-carboxy)phenyl, —(CH 2 )-
  • R 2 is selected from the group consisting of 3-amino-piperidin-1-yl, 3-aminomethyl-pyrrolidin-1-yl, azetidin-1-yl, 3-aminoazetidin-1-yl, pyrrolidin-1-yl, 3-aminocyclopent-1-yl, 3-aminomethylcyclopent-1-yl, 3-aminomethylcyclohex-1-yl, hexahydroazepin-1-yl, 3-aminohexahydroazepin-1-yl, 3-amino-cyclohex-1-yl, piperazin-1-yl, homopiperazin-1-yl, 3-amino-pyrrolidin-1-yl, and R-3-aminopiperidin-1-yl, each substituted or unsubstituted.
  • K is CR 12 , where R 12 is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, alkyl, aryloxy, heteroaryloxy, amino, and alkoxy, each substituted or unsubstituted;
  • R 1 is selected from the group consisting of —(CH 2 )-(2-cyano)phenyl, —(CH 2 )-(3-cyano)phenyl, —(CH 2 )-(2-hydroxy)phenyl, —(CH 2 )-(3-hydroxy)phenyl, —(CH 2 )-(2-alkenyl)phenyl, —(CH 2 )-(3-alkenyl)phenyl, —(CH 2 )-(2-alkyl)phenyl, —(CH 2 )-(3-alkynyl)phenyl, —(CH 2 )-(2-nitro)phenyl, —(CH 2 )-(3-nitro)phenyl, —(CH 2 )-(2-carboxy)phenyl, —(CH 2 )-(3-carboxy)phenyl, —(CH 2 )-(2-carboxamido)phenyl, —(CH 2 )-
  • R 2 is selected from the group consisting of 3-amino-piperidin-1-yl, 3-aminomethyl-pyrrolidin-1-yl, azetidin-1-yl, 3-aminoazetidin-1-yl, pyrrolidin-1-yl, 3-aminocyclopent-1-yl, 3-aminomethylcyclopent-1-yl, 3-aminomethylcyclohex-1-yl, hexahydroazepin-1-yl, 3-aminohexahydroazepin-1-yl, 3-amino-cyclohex-1-yl, piperazin-1-yl, homopiperazin-1-yl, 3-amino-pyrrolidin-1-yl, and R-3-aminopiperidin-1-yl, each substituted or unsubstituted.
  • DPP-IV inhibitors of the present invention comprise a member selected from the group consisting of Formulae IIIa, IIIb, IIIc, IIId, IIIe and IIIf:
  • Q is selected from the group consisting of CO, SO, SO 2 , or C ⁇ NR 9 ;
  • R 1 is hydrogen or is selected from the group consisting of (C 1-10 )alkyl, (C 3-12 )cycloalkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl, aryl(C 1-10 )alkyl, (C 9-12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (C 1-3 )alkyl, imino (C 1-3 )alkyl, amino, cyano, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstitute
  • R 2 is selected from the group consisting of halo, perhalo(C 1-10 )alkyl, amino, cyano, thio, (C 1-10 )alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (C 1-3 )alkyl, imino (C 1-3 )alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, and a substituted or unsubstituted 4, 5, 6 or 7 membered ring;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted; and
  • each R 19 is independently selected from the group consisting of hydrogen, halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, alkyl, alkene, alkyne, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, alkoxy, carbonyl group, imine group, sulfonyl group and sulfmyl group, each substituted or unsubstituted, with the proviso that R 19 is not alkylthio, arylthio, halo, cyano, nitro, and thio in the case where the ring atom to which R 19 is bound is nitrogen.
  • DPP-IV inhibitors of the present invention comprise Formula IV:
  • Q is selected from the group consisting of CO, SO, SO 2 , or C ⁇ NR 9 ;
  • W, X, and Y are each independently selected from the group of moieties where the ring atom is either C, N, O or S;
  • R 1 is hydrogen or is selected from the group consisting of (C 1-10 )alkyl, (C 3-12 )cycloalkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl, aryl(Cl-Io)alkyl, (C 9-12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (C 1-3 )alkyl, imino (C 1-3 )alkyl, amino, cyano, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstit
  • R 2 is selected from the group consisting of halo, perhalo(C 1-10 )alkyl, amino, cyano, thio, (C 1-10 )alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (C 1-3 )alkyl, imino (C 1-3 )alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, and a substituted or unsubstituted 4, 5, 6 or 7 membered ring; and
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted.
  • DPP-IV inhibitors of the present invention comprise Formulae Va, Vb or Vc:
  • Q is selected from the group consisting of CO, SO, SO 2 , or C ⁇ NR 9 ;
  • R 1 is hydrogen or is selected from the group consisting of (C 1-10 )alkyl, (C 3-12 )cycloalkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl, aryl(C 1-10 )alkyl, (C 9-12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (C 1-3 )allyl, imino (C 1-3 )alkyl, amino, cyano, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted
  • R 2 is selected from the group consisting of halo, perhalo(C 1-10 )alkyl, amino, cyano, thio, (C 1-10 )alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (C 1-3 )alkyl, imino (C 1-3 )alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, and a substituted or unsubstituted 4, 5, 6 or 7 membered ring;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted; and
  • each R 19 is independently selected from the group consisting of hydrogen, halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, alkyl, alkene, aycyne, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, alkoxy, carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, with the proviso that R 19 is not alkylthio, arylthio, halo, cyano, nitro, and thio in the case where the ring atom to which R 19 is bound is nitrogen.
  • DPP-IV inhibitors of the present invention comprise Formula VIa or Formula VIb:
  • Q is selected from the group consisting of CO, SO, SO 2 , or C ⁇ NR 9 ;
  • W, X, and Y are each independently selected from the group of moieties where the ring atom is either C, N, O or S;
  • R 1 is hydrogen or is selected from the group consisting of (C 1-10 )alkyl, (C 3-12 )cycloalyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl, aryl(C 1-10 )alkyl, (C 9-12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (C 1-3 )alkyl, imino (C 1-3 )alkyl, amino, cyano, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstitute
  • R 2 is selected from the group consisting of halo, perhalo(C 1-10 )alkyl, amino, cyano, thio, (C 1-10 )alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )aLkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (C 1-3 )alkyl, imino (C 1-3 )alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, and a substituted or unsubstituted 4, 5, 6 or 7 membered ring; and
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted.
  • DPP-IV inhibitors of the present invention comprise Formulae VIIa, VIIb, or VIIc:
  • Q is selected from the group consisting of CO, SO, SO 2 , or C ⁇ NR 9 ;
  • X is selected from the group of moieties where the ring atom is either C, N, O or S in Formula VIIa, or X is selected from the group of moieties where the ring atom is either C or N in Formula VIIb or Formula VIc;
  • R 1 is hydrogen or is selected from the group consisting of (C 1-10 )alkyl, (C 3-12 )cycloalkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl, aryl(C- 1-10 )alkyl, C 9-12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (C 1-3 )aLkyl, imino (C 1-3 )alkyl, amino, cyano, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, muino group, sulfonyl group and sulfinyl group, each substituted or unsubstit
  • R 2 is selected from the group consisting of halo, perhalo(C 1-10 )alkyl, amino, cyano, thio, (C 1-10 )alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (C 1-3 )alkyl, imino (C 1-3 )alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfmyl group, each substituted or unsubstituted, and a substituted or unsubstituted 4, 5, 6 or 7 membered ring;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted; and
  • each R 19 is independently selected from the group consisting of hydrogen, halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, alkyl, alkene, alkyne, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, alkoxy, carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, with the proviso that R 19 is not alkylthio, arylthio, halo, cyano, nitro, and thio in the case where the ring atom to which R 19 is bound is nitrogen.
  • DPP-IV inhibitors of the present invention comprise Formulae VIIIa VIIIb and VIIIc:
  • Q is selected from the group consisting of CO, SO, SO 2 , or C ⁇ NR 9 ;
  • J, K, L, and M are each independently selected from the group of moieties where the ring atom is either C, N, O or S;
  • R 1 is hydrogen or is selected from the group consisting of (C 1-10 )alkyl, (C 3-12 )cycloalkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl, aryl(C 1-10 )alkyl, (C 9-12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (C 1-3 )alkyl, imino (C 1-3 )alkyl, amino, cyano, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfmyl group, each substituted or unsubstituted
  • R 2 is selected from the group consisting of halo, perhalo(C 1-10 )alkyl, amino, cyano, thio, (C 1-10 )alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (C 1-3 )alkyl, imino (C 1-3 )alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, and a substituted or unsubstituted 4, 5, 6 or 7 membered ring; and
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted.
  • DPP-IV inhibitors of the present invention comprise Formula IX:
  • Q is selected from the group consisting of CO, SO, SO 2 , or C ⁇ NR 9 ;
  • J, K, L, and M are each independently selected from the group of moieties where the ring atom is either C, N, O or S;
  • R 1 is hydrogen or is selected from the group consisting of (C 1-10 )alkyl, (C 3-12 )cycloalkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl, aryl(C 1-10 )alkyl, (C 9-12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfMyl (C 1-3 )alkyl, imino (C 1-3 )alkyl, amino, cyano, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted
  • R 2 is selected from the group consisting of halo, perhalo(C 1-10 )alkyl, amino, cyano, thio, (C 1-10 )aLkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfmyl (C 1-3 )alkyl, imino (C 1-3 )alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, and a substituted or unsubstituted 4, 5, 6 or 7 membered ring; and
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted.
  • DPP-IV inhibitors of the present invention comprise Formula X:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • R 1 is —ZR m , where Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and R m is selected from the group consisting of a substituted or unsubstituted (C 3-7 )cycloalkyl and aryl;
  • R 2 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring;
  • R 3 and R 4 are taken together to form a substituted or unsubstituted 5 or 6 membered ring;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted.
  • DPP-IV inhibitors of the present invention comprise Formula XI:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • J, K, L, and M are each independently selected from the group of CR 12 and N;
  • R 1 is —ZR m , where Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and R m is selected from the group consisting of a substituted or unsubstituted (C 3-7 )cycloalkyl and aryl;
  • R 2 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted; and
  • each R 12 is hydrogen or is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF 3 , alkyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, cyano, nitro, alkoxy, a carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted.
  • DPP-IV inhibitors of the present invention comprise Formulae XIIa, XIIb, XIIc, XIId, XIIe, and XIIf:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • R 1 is —ZR m , where Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and R m is selected from the group consisting of a substituted or unsubstituted (C 3-7 )cycloalkyl and aryl;
  • R 2 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted; and
  • each R 19 is independently selected from the group consisting of hydrogen, halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, alkyl, alkene, alkyne, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, alkoxy, carbonyl group, imine group, sulfonyl group and sulfmyl group, each substituted or unsubstituted, with the proviso that R 19 is not alkylthio, arylthio, halo, cyano, nitro, and thio in the case where the ring atom to which R 19 is bound is nitrogen.
  • DPP-IV inhibitors of the present invention comprise Formula XIII:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • W, X, and Y are each independently selected from the group of moieties where the ring atom is either C, N, O or S;
  • R 1 is —ZR m , where Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and R m is selected from the group consisting of a substituted or unsubstituted (C 3-7 )cycloalkyl and aryl;
  • R 2 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted.
  • DPP-IV inhibitors of the present invention comprise Formulae XIVa, XIVb, and XIVc:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • R 1 is -ZR m , where Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and Rm is selected from the group consisting of a substituted or unsubstituted (C 3-7 )cycloalkyl and aryl;
  • R 2 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted; and
  • each R 19 is independently selected from the group consisting of hydrogen, halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, alkyl, alkene, alkyne, aryl, heteroaryl, ainosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, alkoxy, carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, with the proviso that R 19 is not alkylthio, arylthio, halo, cyano, nitro, and thio in the case where the ring atom to which R 19 is bound is nitrogen.
  • DPP-IV inhibitors of the present invention comprise Formulae XVa and XVb:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • W, X, and Y are each independently selected from the group of moieties where the ring atom is either C, N, O or S;
  • R 1 is -ZR m , where Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and R m is selected from the group consisting of a substituted or unsubstituted (C 3-7 )cycloalkyl and aryl;
  • R 2 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted.
  • DPP-IV inhibitors of the present invention comprise Formulae XVIa, XVII, and XVIc:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • X is selected from the group of moieties where the ring atom is either C, N, O or S in Formula XVIa, or X is selected from the group of moieties where the ring atom is either C or N in Formula XVIb or Formula XVIc;
  • R 1 is -ZR m , where Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and R m is selected from the group consisting of a substituted or unsubstituted (C 3-7 )cycloalkyl and aryl;
  • R 2 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted; and
  • each R 19 is independently selected from the group consisting of hydrogen, halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, alkyl, alkene, alkyne, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, alkoxy, carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, with the proviso that R 19 is not alkylthio, arylthio, halo, cyano, nitro, and thio in the case where the ring atom to which R 19 is bound is nitrogen.
  • DPP-IV inhibitors of the present invention comprise Formulae XVIIa, XVIIb, and XVIIc:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • J, K, L, and M are each independently selected from the group of moieties where the ring atom is either C, N, O or S;
  • R 1 is -ZR m , where Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and R m is selected from the group consisting of a substituted or unsubstituted (C 3-7 )cycloalkyl and aryl; and
  • R 2 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring.
  • DPP-IV inhibitors of the present invention comprise Formula XVIII:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • J, K, L, and M are each independently selected from the group of moieties where the ring atom is either C, N, O or S;
  • R 1 is -ZR m , where Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and R m is selected from the group consisting of a substituted or unsubstituted (C 3-7 )cycloalkyl and aryl;
  • R 2 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted.
  • DPP-WV inhibitors of the present invention comprise Formula XIX:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • R 1 is -ZR m , where Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and -R m is selected from the group consisting of a substituted or unsubstituted (C 3-7 )cycloalkyl and aryl;
  • R 2 is -UV, where U is a moiety providing 1-6 atom separation between V and the ring to which R 2 is attached and V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein;
  • R 3 and R4 are taken together to form a substituted or unsubstituted 5 or 6 membered ring;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted.
  • DPP-WV inhibitors of the present invention comprise Formula XX:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • J, K, L, and M are each independently selected from the group of CR 12 and N;
  • R 1 is -ZR m , where Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and -R m is selected from the group consisting of a substituted or unsubstituted (C 3-7 )cycloalkyl and aryl;
  • R 2 is -UV, where U is a moiety providing 1-6 atom separation between V and the ring to which R 2 is attached and V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted; and
  • each R 12 is hydrogen or is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF 3 , alkyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, cyano, nitro, alkoxy, a carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted.
  • DPP-IV inhibitors of the present invention comprise Formulae XXIa, XXIB, XXIc, XXId, XXIe, and XXIf:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • R 1 is -ZR m , where Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and -R m is selected from the group consisting of a substituted or unsubstituted (C 3-7 )cycloalkyl and aryl;
  • R 2 is -UV, where U is a moiety providing 1-6 atom separation between V and the ring to which R 2 is attached and V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted; and
  • each R 19 is independently selected from the group consisting of hydrogen, halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, alkyl, alkene, alkyne, aryl, heteroaryl, arninosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, alkoxy, carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, with the proviso that R 19 is not alkylthio, arylthio, halo, cyano, nitro, and thio in the case where the ring atom to which R 19 is bound is nitrogen.
  • DPP-1V inhibitors of the present invention comprise Formula XXII:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • W, X, and Y are each independently selected from the group of moieties where the ring atom is either C, N, O or S;
  • R 1 is -ZR m , where Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and -R m is selected from the group consisting of a substituted or unsubstituted (C 3-7 )cycloalkyl and aryl;
  • R 2 is -UV, where U is a moiety providing 1-6 atom separation between V and the ring to which R 2 is attached and V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein; and
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted.
  • DPP-IV inhibitors of the present invention comprise Formulae XXIIIa, XXIIIb, and XXIIIc:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • R 1 is -ZR m , where Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and -R m is selected from the group consisting of a substituted. or unsubstituted (C 3-7 )cycloalkyl and aryl;
  • R 2 is -UV, where U is a moiety providing 1-6 atom separation between V and the ring to which R 2 is attached and V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted; and
  • each R 19 is independently selected from the group consisting of hydrogen, halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, alkyl, alkene, alkyne, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, alkoxy, carbonyl group, imine group, sulfonyl group and sulfmyl group, each substituted or unsubstituted, with the proviso that R 19 is not alkylthio, arylthio, halo, cyano, nitro, and thio in the case where the ring atom to which R 19 is bound is nitrogen.
  • DPP-IV inhibitors of the present invention comprise Formulae XXIVa and XXIVb:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • W, X, and Y are each independently selected from the group of moieties where the ring atom is either C, N, O or S;
  • R 1 is -ZR m , where Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and -R m is selected from the group consisting of a substituted or unsubstituted (C 3-7 )cycloalkyl and aryl;
  • R 2 is -UV, where U is a moiety providing 1-6 atom separation between V and the ring to which R 2 is attached and V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein; and
  • R 19 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted.
  • DPP-IV inhibitors of the present invention comprise Formulae XXVa, XXVb, and XXVc:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • X is selected from the group of moieties where the ring atom is either C, N, O or S in Formula XXVa, or X is selected from the group of moieties where the ring atom is either C or N in Formula XXVb or Formula XXVc;
  • R 1 is -ZR m , where Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and -R m is selected from the group consisting of a substituted or unsubstituted (C 3-7 )cycloalkyl and aryl;
  • R 2 is -UV, where U is a moiety providing 1-6 atom separation between V and the ring to which R 2 is attached and V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted; and each R 19 is independently selected from the group consisting of hydrogen, halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, alkyl, alkene, ayyyne, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, alkoxy, carbonyl group, imine group, sulfonyl group and sulfinyl group,
  • DPP-1V inhibitors of the present invention comprise Formulae XXVIa, XXVIb, and XXVIc:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • J, K, L, and M are each independently selected from the group of moieties where the ring atom is either C, N, O or S;
  • R 1 is -ZR m , where Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and -R m is selected from the group consisting of a substituted or unsubstituted (C 3-7 )cycloalkyl and aryl; and
  • R 2 is -UV, where U is a moiety providing 1-6 atom separation between V and the ring to which R 2 is attached and V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein.
  • DPP-IV inhibitors of the present invention comprise Formula XXVII:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • J, K, L, and M are each independently selected from the group of moieties where the ring atom is either C, N, O or S;
  • R 1 is -ZR m , where Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and -R m is selected from the group consisting of a substituted or unsubstituted (C 3-7 )cycloalkyl and aryl;
  • R 2 is -UV, where U is a moiety providing 1-6 atom separation between V and the ring to which R 2 is attached and V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein; and
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted.
  • DPP-IV inhibitors of the present invention comprise Formula XXVIII:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • R 1 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring;
  • R 2 is -WV, where U is a moiety providing 1-6 atom separation between V and the ring to which R 2 is attached and V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein;
  • R 3 and R 4 are taken together to form a substituted or unsubstituted 5 or 6 membered ring;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted.
  • DPP-IV inhibitors of the present invention comprise Formula XXIX:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • J, K, L, and M are each independently selected from the group of CR 12 and N;
  • R 1 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring;
  • R 2 is -UV, where U is a moiety providing 1-6 atom separation between V and the ring to which R 2 is attached and V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted; and
  • each R 12 is hydrogen or is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF 3 , alkyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, cyano, nitro, alkoxy, a carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted.
  • DPP-IV inhibitors of the present invention comprise Formulae XXXa, XXXb, XXXc, XXXd, XXXe, and XXXf:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • R 1 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring;
  • R 2 is -WV, where U is a moiety providing 1-6 atom separation between V and the ring to which R 2 is attached and V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted; and
  • each R 1 9 is independently selected from the group consisting of hydrogen, halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, alkyl, alkene, ayne, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, alkoxy, carbonyl group, imine group, sulfonyl group and sulfmyl group, each substituted or unsubstituted, with the proviso that R 19 is not alkylthio, arylthio, halo, cyano, nitro, and thio in the case where the ring atom to which R 19 is bound is nitrogen.
  • DPP-IV inhibitors of the present invention comprise Formula XXXI:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • W, X, and Y are each independently selected from the group of moieties where the ring atom is either C, N, O or S;
  • R 1 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring;
  • R 2 is -UV, where U is a moiety providing 1-6 atom separation between V and the ring to which R 2 is attached and V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein; and
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted.
  • DPP-IV inhibitors of the present invention comprise Formulae XXXIIa, XXXIIb, and XXXIIc:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • R 1 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring;
  • R 2 is -UV, where U is a moiety providing 1-6 atom separation between V and the ring to which R 2 is attached and V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted; and
  • each R 19 is independently selected from the group consisting of hydrogen, halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, alkyl, alkene, alkyne, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, alkoxy, carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, with the proviso that R 19 is not alkylthio, arylthio, halo, cyano, nitro, and thio in the case where the ring atom to which R 19 is bound is nitrogen.
  • DPP-IV inhibitors of the present invention comprise Formulae XXXIIIa and XXXIIIb:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • W, X, and Y are each independently selected from the group of moieties where the ring atom is either C, N, O or S;
  • R 1 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring;
  • R 2 is -UV, where U is a moiety providing 1-6 atom separation between V and the ring to which R 2 is attached and V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein; and
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted.
  • DPP-WV inhibitors of the present invention comprise Formulae XXXIVa, XXXIVb, and XXXIVc:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • X is selected from the group of moieties where the ring atom is either C, N, O or S in Formula XXXIVa, or X is selected from the group of moieties where the ring atom is either C or N in Formula XXXIb or Formula XXXIVc;
  • R 1 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring;
  • R 2 is -UV, where U is a moiety providing 1-6 atom separation between V and the ring to which R 2 is attached and V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted; and
  • each R 19 is independently selected from the group consisting of hydrogen, halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, alkyl, alkene, alkyne, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, alkoxy, carbonyl group, imine group, sulfonyl group and sulfmyl group, each substituted or unsubstituted, with the proviso that R 19 is not alkylthio, arylthio, halo, cyano, nitro, and thio in the case where the ring atom to which R 19 is bound is nitrogen.
  • DPP-IV inhibitors of the present invention comprise Formulae XXXVa, XXXVb, and XXXVc:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • J, K, L, and M are each independently selected from the group of moieties where the ring atom is either C, N, O or S;
  • R 1 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring;
  • R 2 is -UV, where U is a moiety providing 1-6 atom separation between V and the ring to which R 2 is attached and V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein.
  • DPP-IV inhibitors of the present invention comprise Formula
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • J, K, L, and M are each independently selected from the group of moieties where the ring atom is either C, N, O or S;
  • R 1 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring;
  • R 2 is -UV, where U is a moiety providing 1-6 atom separation between V and the ring to which R 2 is attached and V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein; and
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted.
  • DPP-IV inhibitors of the present invention comprise Formula XXXVII:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • J, K, L, and M are each independently selected from the group of CR 1 2 and N, provided that at least one of K and L is CR 12 where R 12 is not hydrogen;
  • R 1 is -ZR m , where Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and R m is selected from the group consisting of a substituted or unsubstituted (C 3-7 )cycloalkyl and aryl;
  • R 2 is -UV, where U is a moiety providing 1-6 atom separation between V and the ring to which R 2 is attached and V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted; and each R 12 is hydrogen or is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF 3 , alkyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, cyano, nitro, alkoxy, a carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted; and
  • DPP-IV inhibitors of the present invention comprise Formula XXXVIII:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • J, K, L, and M are each independently selected from the group of CR 12 and N, provided that at least one of K and L is CR 12 where R 12 is not hydrogen;
  • R 1 is -ZR m , where Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and R m is selected from the group consisting of a substituted or unsubstituted (C 3-7 )cycloalkyl and aryl;
  • R 2 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring;
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted; and each R 12 is hydrogen or is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF 3 , alkyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, cyano, nitro, alkoxy, a carbonyl group, imine group, sulfonyl group and sulfmyl group, each substituted or unsubstituted; and each
  • DPP-IV inhibitors of the present invention comprise Formula XXXIX:
  • Q is selected from the group consisting of CO, CS, SO, SO 2 , or C ⁇ NR 9 ;
  • J, K, L, and M are each independently selected from the group of CR 1 2 and N, provided that at least one of K and L is CR 12 where R 12 is not hydrogen;
  • R 1 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring;
  • R 2 is -UV, where U is a moiety providing 1-6 atom separation between V and the ring to which R 2 is attached and V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein; and
  • R 9 is hydrogen or is selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl, each substituted or unsubstituted; and each R 12 is hydrogen or is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF 3 , alkyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, cyano, nitro, alkoxy, a carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted; and
  • R 3 and R 4 are taken together to form an unsubstituted or substituted 5 or 6 membered cycloalkyl or heterocycloalkyl ring.
  • R 3 and R 4 are taken together to form a substituted or unsubstituted phenyl ring.
  • R 3 and R 4 are taken together to form a substituted or unsubstituted heteroaryl ring.
  • R 3 and R 4 are taken together to form a substituted or unsubstituted heteroaryl selected from the group consisting of substituted or unsubstituted furan, thiophene, pyrrole, pyrazole, triazole, isoxazole, oxazole, thiazole, isothiazole, oxadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, benzofuran, isobenzofuran, benzothiophene, isobenzothiophene, imidazole, benzimidazole, indole, isoindole, quinoline, isoquinoline, cinnoline, quinazoline, naphthyridine, pyridopyridine, quinoxaline, phthalazine, and benzothiazole.
  • R 3 and R 4 are taken together to form a 5 or 6-membered ring where the ring comprises at least one CO group.
  • R 3 and R 4 are taken together to form a 5 or 6-membered ring comprising of 1-3 nitrogen ring atoms.
  • R 3 and R 4 are taken together to form a 5 or 6-membered ring where the ring comprises a sulfur atom.
  • the ring sulfur atom is in an oxidized form as SO or S02.
  • R 3 and R 4 are taken together to form a ring system such that the compound formed is selected from the group consisting of substituted or unsubstituted 4-oxo-4H-quinazoline, 3H-pyrido[2,3-d]pyrimidin4-one, 3H-pyrido[3,2-d]pyrimidin4-one, 3H-pyrido[3,4-d]pyrimidin-4-one and 3H-pyrido[4,3-d]pyrimidin4-one.
  • the ring formed by R 3 and R 4 comprises substituents that form a ring fused to the ring formed by R 3 and R 4 .
  • the fused ring may be further substituted or unsubstituted, and may be a saturated or unsaturated ring.
  • the fused ring is a heterocyclic ring.
  • the 5 or 6 membered ring is further substituted such that a 3, 4, 5, 6 or 7 membered bridging ring is formed with the 5 or 6 membered ring.
  • the 3, 4, 5, 6 or 7 membered ring may be further substituted or unsubstituted, and may be a saturated or unsaturated ring.
  • the 3, 4, 5, 6 or 7 membered bridged ring may be a heterocyclic ring.
  • J, K, L and M each comprises a carbon ring atom.
  • J comprises a nitrogen ring atom.
  • K comprises a nitrogen ring atom.
  • L comprises a nitrogen ring atom.
  • M comprises a nitrogen ring atom.
  • J and L each comprise a nitrogen ring atom or J and K each comprise a nitrogen ring atom.
  • K and L each comprise a nitrogen ring atom.
  • K and M each comprise a nitrogen ring atom.
  • J and M each comprise a nitrogen ring atom, or L and M each comprise a nitrogen ring atom.
  • At least one of J, K, L and M comprise a nitrogen ring atom.
  • at least two of J, K, L and M comprise a nitrogen ring atom.
  • at least three of J, K, L and M comprise a nitrogen ring atom.
  • at least three of J, K, L and M comprise a nitrogen ring atom.
  • the ring formed by J, K, L, and M may comprise substituents that form a ring fused or bridged (e.g., through available valencies) to the ring formed by J, K, L, and M.
  • J and M optionally form a fused or bridged ring relative to the ring formed by J, K, L, and M.
  • K is CR 12 , where R 12 is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF 3 , alkyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, cyano, nitro, alkoxy, a carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted.
  • R 12 is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF 3 , alkyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, aryl
  • K is CR 12 , where R 12 is independently selected from the group consisting of halo, perhalo(C 1-0 )alkyl, CF 3 , cyano, nitro, alkyl, aryloxy, heteroaryloxy, amino, and alkoxy, each substituted or unsubstituted.
  • K is CR 12 , where R 12 is independently selected from the group consisting of heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryl, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, thio, a carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted.
  • K is CR 12 , where R 12 is independently selected from the group consisting of chloro, bromo, fluoro, iodo, methoxy, morpholin4-yl, and pyrrolidin-1-yl, each substituted or unsubstituted.
  • L comprises a nitrogen ring atom.
  • L is CR 12 , where R 12 is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF 3 , alkyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, cyano, nitro, alkoxy, a carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted.
  • R 12 is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF 3 , alkyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, aryl
  • L is CR 12 , where R 12 is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, alkyl, aryloxy, heteroaryloxy, amino, morpholin4-yl, and pyrrolidin-1-yl, and alkoxy, each substituted or unsubstituted.
  • J and M form a bridged ring relative to the ring formed by J, K, L, and M
  • K and L are independently CR 12 , where R 12 is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, alkyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, alkoxy, a carbonyl group, imine group, sulfonyl group and sulfmyl group, each substituted or unsubstituted.
  • R 12 is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, alkyl, aryl, heteroaryl, aminosulfonyl, alkyls
  • K is CR 12 , where R 12 is independently selected from the group consisting of halo, perhalo(C 1-10 )aLkyl, CF 3 , cyano, nitro, alkyl, axyl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, alkoxy, a carbonyl group, imine group, sulfonyl group and sulfinyl group, each substituted or unsubstituted; and
  • At least one R 12 is halogen.
  • At least one R 12 is fluorine.
  • At least one of W, X, and Y is CO. In another variation, at least one of W, X, and Y is SO. In another variation, at least one of W, X, and Y is SO 2 . In one variation of each of the above embodiments and variations comprising W, W is selected from the group consisting of CO, SO or SO 2 . In one variation of each of the above embodiments and variations comprising Y, Y is selected from the group consisting of CO, SO or SO 2 .
  • At least one of W, X, and Y comprises a ring nitrogen atom. In yet another variation, at least two of W, X, and Y comprises a ring nitrogen atom. In yet another variation, W comprises a ring nitrogen atom. In still variation, X comprises a ring nitrogen atom. In a further variation, Y comprises a ring nitrogen atom.
  • W and Y are taken together to form a substituted or unsubstituted bridged ring relative to the ring formed by W, X and Y.
  • at least two (ie., two or three) of W, X, and Y are taken together to form a substituted or unsubstituted ring fused or bridged (e.g., by substitution through available valencies) to the ring formed by W, X and Y.
  • W, X, and Y are selected such that the compound comprises a ring system selected from the group consisting of 4-oxo4H-thieno[3,2-d]pyrimidine, 7-oxo-1,2,3,7-tetrahydro-8-thia4,6diaza-cyclopenta[a]indene, 7-methyl-6-oxo-6,7dihydro-purine, and 6-oxo-6,9-dihydro-purine, each substituted or unsubstituted.
  • a ring system selected from the group consisting of 4-oxo4H-thieno[3,2-d]pyrimidine, 7-oxo-1,2,3,7-tetrahydro-8-thia4,6diaza-cyclopenta[a]indene, 7-methyl-6-oxo-6,7dihydro-purine, and 6-oxo-6,9-dihydro-purine, each substituted or unsubstituted.
  • R 1 is selected from the group consisting of —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —NHC 1-3 -alkyl, and —N(C 1-3 -alkyl) 2 , each unsubstituted or substituted through available valencies.
  • R 1 is selected from the group consisting of a (C 1-3 )alkyl; an amino, alkyl, or alkoxy carbonyl (C 1-3 )alkyl; an amino, alkyl, or alkoxy thiocarbonyl (C 1-3 )alkyl; an amino, alkyl, or alkoxy sulfonyl (C 1-3 )alkyl; an amino, alkyl, or alkoxy sulfinyl (C 1-3 )alkyl; an amino, alkyl, or alkoxy imino (C 1-3 )alkyl; and an aryl (C 1-5 )alkyl, each unsubstituted or substituted through available valencies.
  • R 1 is selected from the group consisting of a (C 2-10 )alkenyl; an amino, alkyl, or alkoxy carbonyl (C 1-3 )alkenyl; an amino, alkyl, or alkoxy thiocarbonyl (C 1-3 )alkenyl; an amino, alkyl, or alkoxy sulfonyl (C 1-3 )alkenyl; an amino, alkyl, or alkoxy sulfinyl (C 1-3 )alkenyl; an amino, alkyl, or alkoxy imino (C 1-3 )alkenyl; an aryl (C 1-5 )alkenyl; and a heteroaryl (C 1-5 ) alkenyl, each unsubstituted or substituted through available valencies.
  • a (C 2-10 )alkenyl an amino, alkyl, or alkoxy carbonyl (C 1-3 )alkenyl; an amino, alkyl, or
  • R 1 is selected from the group consisting of a (C 2-10 )alkynyl; an amino, alkyl, or alkoxy carbonyl (C 1-3 )alkynyl; an amino, alkyl, or alkoxy thiocarbonyl (C 1-3 )alkynyl; an amino, alkyl, or alkoxy sulfonyl (C 1-3 )alkynyl; an amino, alkyl, or alkoxy sulfinyl (C 1-3 )alkynyl; an amino, alkyl, or alkoxy imino (C 1-3 )alkynyl; an aryl (C 1-5 ) alkynyl; and heteroaryl (C 1-5 )alkynyl, each unsubstituted or substituted through available valencies.
  • a (C 2-10 )alkynyl an amino, alkyl, or alkoxy carbonyl (C 1-3 )alkynyl;
  • R 1 is substituted or unsubstituted (C 3-7 )cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted phenyl.
  • R 1 is hydroxy.
  • R 1 is —OR 11 , where R 11 is selected from the group consisting of substituted or unsubstituted alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl.
  • R 1 is a carbonyl group. In yet another variation, R 1 is selected from the group consisting of an aldehyde, acid, amide, and ester.
  • R 1 is selected from the group consisting of pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, and morpholin4-ylcarbonyl, each unsubstituted or substituted through available valencies.
  • R 1 is -Z—R m , where Z is a moiety having a chain of 1-6 atoms selected from the group consisting of substituted or unsubstituted C, N, O, and S, attaching -R m to the ring, or Z is a unsubstituted or substituted -(C 1-3 )alkylene optionally interrupted by O, N(O), —NH, SO, SO 2 , or carbonyl; and
  • -R m is selected from the group consisting of a substituted or unsubstituted (C 1-7 )alkyl, -(C 2-7 )alkene, -(C 2-7 )alkne, -(C 3-7 )cycloalkyl, and aryl.
  • R 1 is -ZR m , where
  • Z is a moiety providing 1-6 atom separation between R m and the ring to which R 1 is attached, and
  • R m is selected from the group consisting of a substituted or unsubstituted (C 3-7 )cycloalkyl and aryl.
  • the 1-6 atoms of Z comprise of carbon atoms.
  • the 1-6 atoms of Z are selected from the group consisting of at least one oxygen, or at least one nitrogen atom.
  • Z comprises of 1 atom.
  • Z is selected from the group consisting of —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —C(O)—, —CH 2 C(O)—, —C(O)CH 2 —, —CH 2 —C(O)CH 2 —, —C(O)CH 2 CH 2 —, —CH 2 CH 2 C(O)—, —O—, —OCH 2 —, —CH 2 O—, —CH 2 OCH 2 —, —OCH 2 CH 2 —, —CH 2 CH 2 O—, —N(CH 3 )—, —NHCH 2 —, —CH 2 NH—, —CH 2 NHCH 2 —, —NHCH 2 CH 2 —, —CH 2 CH 2 NH—, —NH—C(O)—, —NCH 3 —C(O)—, —C(O)NH—, —C(O)—, —C
  • Z is selected from the group consisting of —CH 2 —, —C(O)—, —CH 2 C(O)—, —C(O)CH 2 —, —CH 2 —C(O)CH 2 —, —C(O)CH 2 CH 2 —, and —CH 2 CH 2 C(O)—, each substituted or unsubstituted.
  • Z provides 1-3 atom separation between R m and the ring.
  • Z provides 1 atom separation between R m and the ring.
  • the 1 atom separation is provided by an atom selected from the group consisting of C, N, O, and S.
  • the 1 atom separation is provided by a carbon atom.
  • the 1 atom separation is provided by an oxygen atom.
  • the 1 atom separation is provided by a nitrogen atom.
  • Z is selected from the group consisting of —CH 2 —, —CHR9—, —C(R 9 )(R 9 )—, —C(O)—, —C(S)—, —C(NH)—, —C(NR 9 )—, —O—, —N(H)—, —N(R 9 )—, and —S—.
  • Z is a carbonyl
  • R m is a substituted or unsubstituted (C 3-7 )cycloalkyl.
  • R m is a substituted or unsubstituted aryl.
  • R m is a substituted or unsubstituted phenyl.
  • R m is a ring having a non-hydrogen substituent at a 2 or 3 position of the ring.
  • R m has a non-hydrogen substituent at a 2 or 3 position of the ring selected from the group consisting of (C 1-10 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, (C 9-12 )bicycloaryl, hetero(C 4-12 )bicycloaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (CI- 3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfinyl (C 1-3 )alkyl, imino (C 1-3 )alkyl, amino, aryl, heteroaryl, hydroxy, alkoxy,
  • R m is selected from the group consisting of alkyl, cycloalkyl, aryl, arylalkyl, heteroarylalkyl, and bicycloaryl, each substituted or unsubstituted.
  • R m is selected from the group consisting of (2-cyano)phenyl, (3-cyano)phenyl, (2-hydroxy)phenyl, (3-hydroxy)phenyl, (2-alkenyl)phenyl, (3-alkenyl)phenyl, (2-alkynyl)phenyl, (3-alkynyl)phenyl, (2-nitro)phenyl, (3-nitro)phenyl, (2-carboxy)phenyl, (3-carboxy)phenyl, (2-carboxamido)phenyl, (3-carboxamido)phenyl, (2-sulfonamido)phenyl, (3-sulfonamido)phenyl, (2-tetrazolyl)phenyl, (3-tetrazolyl)phenyl, (2-aminomethyl)phenyl, (3-aminomethyl)phenyl, (2-amnin
  • R 1 is —(CR 5 R 6 ) 0-2 —(R 7 ) 0-2 —R 8 , where R 5 and R 6 are each independently hydrogen, halo or substituted or unsubstituted (C 1-8 )alkyl or R 5 and R 6 are taken together to form a (C 3-6 )cycloalkyl ring;
  • R 7 is selected from the group consisting of CO; CS; (C 1-10 )alkylene, (C 3-12 )cycloalkylene, hetero(C 3-12 )cycloalkylene, amino, arylene, heteroarylene, imine, sulfonyl, and sulfinyl, each substituted or unsubstituted; and
  • R 8 is hydrogen or is selected from the group consisting of (C 1-7 )alkyl, (C 2-7 )alkenyl, (C 2-7 )alkynyl, (C 3-7 )cycloalkyl, (C 3-7 )heterocycloalkyl, aryl, aryl(C 1-3 )alkyl, heteroaryl(C 1-2 )alkyl, heteroaryl, —SH, (C 1-7 )alkyl-S—, (C 1-7 )alkyl-SO—, (C 1-7 )alkyl-SO 2 —, CO, CS, NHCONNH 2 , —NHCSNH 2 , —NHCONH 2 , —NHCO(C 1-7 )alkyl, —NHSO 2 (C 1-7 )alkyl, —OCO-(C 1-5 )alkyl, cyano, nitro, halo, hydroxy, perhalo(C 1-7 )alkyl,
  • R 1 is selected from the group consisting of —(CH 2 )-(2-cyano)phenyl, —(CH 2 )-(3-cyano)phenyl, —(CH 2 )-(2-hydroxy)phenyl, —(CH 2 )-(3-hydroxy)phenyl, —(CH 2 )-(2-alkenyl)phenyl, —(CH 2 )-(3-alkenyl)phenyl, —(CH 2 )-(2-alkynyl)phenyl, —(CH 2 )-(3-alykenyl)phenyl, —(CH 2 )-(2-nitro)phenyl, —(CH 2 )-(3-nitro)phenyl, —(CH 2 )-(2-carboxy)phenyl, —(CH 2 )-(3-carboxy)phenyl, —(CH 2 )-(2-carboxamido)phenyl,
  • R 1 is selected from the group consisting of -(C 1 )alkyl-aryl, -(C 1 )alkyl-bicycloaryl, -aminoaryl, -aminoheteroaryl, -aminobicycloaryl, -aminoheterobicycloaryl, —O-aryl, —O-heteroaryl, —O-bicycloaryl, —O-heterobicycloaryl, —(S)-aryl, —(S)-heteroaryl, —(S)-bicycloaryl, —S-heterobicycloaryl, —C(O)-aryl, —C(O)-heteroaryl, —C(O)-bicycloaryl, —C(O)-heterobicycloaryl, —C(S)-aryl, —(S)-aryl, —(S)
  • R 1 is a substituted or unsubstituted aryl. In a further variation of each of the above embodiments and variations comprising R 1 , R 1 is a substituted or unsubstituted phenyl. In yet another variation of each of the above embodiments and variations comprising R 1 , R 1 is a substituted or unsubstituted heteroaryl.
  • R 2 is selected from the group consisting of halo, perhalo(C 1-10 )alkyl, amino, cyano, thio, (C 1-10 )alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbonyl (C 1-3 )alkyl, thiocarbonyl (C 1-3 )alkyl, sulfonyl (C 1-3 )alkyl, sulfMyl (C 1-3 )alkyl, imino (C 1-3 )alkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, and a substituted or unsubstituted 4, 5, 6 or 7 membered ring.
  • R 2 is selected from the group consisting of (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(CI- 5 )alkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, and (C 9-12 )bicycloaryl(C 1-5 )alkyl, each substituted or unsubstituted.
  • R 2 is selected from the group consisting of I, Br, Cl, and F.
  • R 2 is selected from the group consisting of —SH, —SCH 3 , and —S(C 1-3 )alkyl unsubstituted or substituted through available valencies.
  • R 2 is selected from the group consisting of —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —NH(C 1-3 )alkyl, —N(C 1-3 -alkyl) 2 , -NR14R 15 , where R 14 is selected from the group consisting of a substituted or unsubstituted (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, (C 6-12 )aryl, hetero(C 5-12 )aryl, (C 9-12 )bicycloaryl and hetero(C 4-12 )bicycloaryl, and R 15 is selected from the group consisting of hydrogen and a substituted or unsubstituted (C 1-8 )alkyl, and —NR 10 R 11 , where R 10 and -R 11 together are —(CH 2 ) 4-5 — optionally interrupted by one O, S, NH or —N(C
  • R 2 is selected from the group consisting of a (C 1-3 )alkyl; an amino, alkyl, or alkoxy carbonyl (C 1-3 )alkyl; an amino, alkyl, or alkoxy thiocarbonyl (C 1-3 )alkyl; an amino, alkyl, or alkoxy sulfonyl (C 1-3 )alkyl; an amino, alkyl, or alkoxy sulfinyl (C 1-3 )alkyl; an amino, alkyl, or alkoxy imino (C 1-3 )alkyl; an aryl (C 1-5 )alkyl; and a heteroaryl (C 1-5 )alkyl, each unsubstituted or substituted through available valencies.
  • R 2 is selected from the group consisting of a (C 2-10 )alkenyl; an amino, alkyl, or alkoxy carbonyl (C 1-3 )alkenyl; an amino, alkyl, or alkoxy thiocarbonyl (C 1-3 )alkenyl; an amino, alkyl, or alkoxy sulfonyl (C 1-3 )alkenyl; an amino, alkyl, or alkoxy sulfinyl (C 1-3 )alkenyl; an amino, alkyl, or alkoxy imino (C 1-3 )alkenyl; an aryl (C 1-5 )alkenyl, and a heteroaryl (C 1-5 )alkenyl, each unsubstituted or substituted through available valencies.
  • a (C 2-10 )alkenyl an amino, alkyl, or alkoxy carbonyl (C 1-3 )alkenyl; an amino, alkyl, or
  • R 2 is selected from the group consisting of a (C 2-10 )alkynyl; an amino, alkyl, or alkoxy carbonyl (C 1-3 )alkynyl; an amino, alkyl, or alkoxy thiocarbonyl (C 1-3 )alkynyl; an amino, alkyl, or alkoxy sulfonyl (C 1-3 )alkqnyl; an amino, alkyl, or alkoxy sulfinyl (C 1-3 )alknyl; an amino, alkyl, or alkoxy imino (C 1-3 )alkynyl; an aryl (C 1-5 ) alknyl; and a heteroaryl (C 1-5 )alkynyl, each unsubstituted or substituted through available valencies.
  • a (C 2-10 )alkynyl an amino, alkyl, or alkoxy carbonyl (C 1-3 )alkyn
  • R 2 is a substituted or unsubstituted 3, 4, 5, 6, or 7 membered ring.
  • R 2 is substituted or unsubstituted (C 3-7 )cycloalkyl (ie., a substituted or unsubstituted 3, 4, 5, 6, or 7 membered cycloalkyl).
  • R 2 is substituted or unsubstituted (C 3-7 )heterocycloalkyl (e.g., a substituted or unsubstituted 4, 5, 6,or 7 membered heterocycloalkyl).
  • R 2 is substituted or unsubstituted aryl.
  • R 2 is substituted or unsubstituted phenyl.
  • R 2 is substituted or unsubstituted heteroaryl.
  • R 2 is hydroxy
  • R 2 is —OR 11 , where R 11 is selected from the group consisting of substituted or unsubstituted alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, bicycloaryl, and heterobicycloaryl.
  • R 2 is a carbonyl group.
  • R 2 is selected from the group consisting of an aldehyde, acid, amide, ketone and ester.
  • R 2 is selected from the group consisting of pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, and morpholin-4-ylcarbonyl, each unsubstituted or substituted through available valencies.
  • R 2 is selected from the group consisting of 3-amino-piperidin-1-yl, 3-aniinomethyl-pyrrolidin-1-yl, azetidin-1-yl, 3-aminoazetidin-1-yl, pyrrolidin-1-yl, 3-aminocyclopent-1-yl, 3-aminomethylcyclopent-1-yl, 3-aminomethylcyclohex-1-yl, hexahydroazepin-1-yl, 3-aminohexahydroazepin-1-yl, 3-amino-cyclohex-1-yl, piperazin-1-yl, homopiperazin-1-yl, 3-amino-pyrrolidin-1-yl, and R-3-aminopiperidin-1-yl, each substituted or unsubstituted.
  • R 2 is MR a R b , where
  • M is CH or N
  • R a is H or (C 1-6 )alkyl
  • R b is amino(C 0-4 )alkyl
  • M together with R a and R b form a ring of 4-7 atoms selected from the group consisting of C, N, O, and S each is independently substituted or unsubstituted and where C, N and S are optionally oxidized.
  • R 2 comprises a primary or secondary amine where the nitrogen of the amine is 1-6 atoms from the nearest ring atom. In another particular variation, R 2 comprises a primary or secondary amine where the nitrogen of the amine is 2-5 atoms from the nearest ring atom. In yet another variation, R 2 comprises a primary or secondary amine where the nitrogen of the amine is 3-4 atoms from the nearest ring atom.
  • R 2 is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring wherein at least one substituent is selected from the group consisting of a primary, secondary or tertiary amine, a heterocycloalkyl comprising a nitrogen ring atom, and a heteroaryl comprising a nitrogen ring atom.
  • R 2 is selected from the group consisting of
  • each R 9 is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, hydroxy, alkyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, alkoxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted.
  • R 2 is selected from the group consisting of
  • each R 8 is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, hydroxy, alkyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, alkoxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted.
  • R 2 is a substituted or unsubstituted heteroaryl selected from the group consisting of furan, thiophene, pyrrole, pyrazole, triazole, isoxazole, oxazole, thiazole, isothiazole, oxadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, benzofuran, isobenzofuran, benzothiophene, isobenzothiophene, imidazole, benzimidazole, indole, isoindole, quinoline, isoquinoline, cinnoline, quinazoline, naphthyridine, pyridopyridine, quinoxaline, phthalazine, and benzothiazole, each substituted or unsubstituted.
  • R 2 is selected from the group consisting of (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, aryl(C 1-10 )alkyl, heteroaryl (C 1-5 )alkyl, (C 9-12 )bicycloaryl, and hetero(C 4-12 )bicycloaryl, each substituted or unsubstituted.
  • R 2 is a substituted or unsubstituted (C 3-7 )cycloalkyl ring, optionally comprising O, N(O), N, S, SO, SO 2 or a carbonyl group in the ring.
  • U provides 14 atom separation between V and the ring.
  • U provides 1-3 atom separation between V and the ring.
  • U is selected from the group consisting of —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —C(O)—, —CH 2 C(O)—, —C(O)CH 2 —, —CH 2 —C(O)CH 2 —, —C(O)CH 2 CH 2 —, —CH 2 CH 2 C(O)—, —O—, —OCH 2 —, —CH 2 O—, —CH 2 OCH 2 —, —OCH 2 CH 2 —, —CH 2 CH 2 0—, —N(CH 3 )—, —NHCH 2 —, —CH 2 NH—, —CH 2 NHCH 2 —, —NHCH 2 CH 2 —, —CH 2 CH 2 NH—, —NH—C(O)—, —NCH 3 —C(O)—, —C(O)NH—, —
  • U is selected from the group consisting of —CH 2 —, —CHR 9 —, —C(R 9 )(R 9 )—, —O—, —N(H)—, —N(R 9 )—, and —S—.
  • V is selected from the group consisting of a primary, secondary or tertiary amine, a heterocycloalkyl comprising a nitrogen ring atom, and a heteroaryl comprising a nitrogen ring atom
  • V is selected from the group consisting of a substituted or unsubstituted 3, 4, 5, 6 or 7 membered ring wherein at least one substituent is selected from the group consisting of a primary, secondary or tertiary amine, a heterocycloalkyl comprising a nitrogen ring atom, and a heteroaryl comprising a nitrogen ring atom.
  • the basic nitrogen of V forms part of a primary, secondary or tertiary amine.
  • the basic nitrogen of V is a nitrogen ring atom of a heterocycloalkyl comprising a nitrogen ring atom or a heteroaryl comprising a nitrogen ring atom.
  • -UV is selected from the group consisting of
  • each R 8 is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, hydroxy, alkyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, alkoxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, with the proviso that at least one R 8 serves as V.
  • -UV is selected from the group consisting of
  • each R 8 is independently selected from the group consisting of halo, perhalo(C 1-10 )alkyl, CF 3 , cyano, nitro, hydroxy, alkyl, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, amino, thio, alkoxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, with the proviso that at least one R 8 serves as V.
  • At least one R 8 is a primary, secondary or tertiary amine.
  • At least one R 8 is a substituted or unsubstituted heterocycloalkyl comprising a nitrogen ring atom or a substituted or unsubstituted heteroaryl comprising a nitrogen ring atom.
  • At least one R 8 is selected from the group consisting of —NH 2 , —NH(C 1-5 alkyl), —N(C 1-5 alkyl) 2 , piperazine, imidazole, and pyridine.
  • R 1 is selected from the group consisting of —(CH 2 )-(2-cyano)phenyl, —(CH 2 )-(3-cyano)phenyl, —(CH 2 )-(2-hydroxy)phenyl, —(CH 2 )-(3-hydroxy)phenyl, —(CH 2 )-(2-alkenyl)phenyl, —(CH 2 )-(3-alkenyl)phenyl, —(CH 2 )-(2-alkynyl)phenyl, —(CH 2 )-(3-alkynyl)phenyl, —(CH 2 )-(2-nitro)phenyl, —(CH 2 )-(3-nitro)phenyl, —(CH 2 )-(2-carboxy)phenyl, —(CH 2 )-(3-carboxy)phenyl, —(CH 2 )-(2-carboxamid
  • R 2 is selected from the group consisting of 3-amino-piperidin-1-yl, 3-aminomethyl-pyrrolidin-1-yl, azetidin-1-yl, 3-aminoazetidin-1-yl, pyrrolidin-1-yl, 3-aminocyclopent-1-yl, 3-aminomethylcyclopent-1-yl, 3-aminomethylcyclohex-1-yl, hexahydroazepin-1-yl, 3-aminohexahydroazepin-1-yl, 3-amino-cyclohex-1-yl, piperazin-1-yl, homopiperazin-1-yl, 3-amino-pyrrolidin-1-yl, and R-3-aminopiperidin-1-yl, each substituted or unsubstituted.
  • R 1 is selected from the group consisting of —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —NHC 1-3 -alkyl, and —N(C 1-3 -alkyl) 2 each unsubstituted or substituted through available valencies
  • R 2 is selected from the group consisting of 3-amino-piperidin-1-yl, 3-aminomethyl-pyrrolidin-1-yl, azetidin-1-yl, 3-aminoazetidin-1-yl, pyrrolidin-1-yl, 3-aminocyclopent-1-yl, 3-aminomethylcyclopent-1-yl, 3-aminomethylcyclohex-1-yl, hexahydroazepin-1-yl, 3-aminohexahydroazepin-1-yl, 3-amino-cyclohex-1-yl, piperazin-1-y
  • R 1 is selected from the group consisting of —(CH 2 )-(2-cyano)phenyl, —(CH 2 )-(3-cyano)phenyl, —(CH 2 )-(2-hydroxy)phenyl, —(CH 2 )-(3-hydroxy)phenyl, —(CH 2 )-(2-alkenyl)phenyl, —(CH 2 )-(3-alkenyl)phenyl, —(CH 2 )-(2-alkyl)phenyl, —(CH 2 )-(3-aynyl)phenyl, —(CH 2 )-(2-nitro)phenyl, —(CH 2 )-(3-nitro)phenyl, —(CH 2 )-(2-carboxy)phenyl, —(CH 2 )-(3-carboxy)phenyl, —(CH 2 )-(2-carboxamido)phenyl, —(CH 2 )-
  • R 2 is selected from the group consisting of 3-amino-piperidin-1-yl, 3-aminomethyl-pyrrolidin-1-yl, azetidin-1-yl, 3-aminoazetidin-1-yl, pyrrolidin-1-yl, 3-aminocyclopent-1-yl, 3-aminomethylcyclopent-1-yl, 3-aminomethylcyclohex-1-yl, hexahydroazepin-1-yl, 3-aminohexahydroazepin-1-yl, 3-amino-cyclohex-1-yl, piperazin-1-yl, homopiperazin-1-yl, 3-amino-pyrrolidin-1-yl, and R-3-aminopiperidin-1-yl, each substituted or unsubstituted.
  • R 1 is selected from the group consisting of —(CH 2 )-(2-cyano)phenyl, —(CH 2 )-(3-cyano)phenyl, —(CH 2 )-(2-hydroxy)phenyl, —(CH 2 )-(3-hydroxy)phenyl, —(CH 2 )-(2-alkenyl)phenyl, —(CH 2 )-(3-alkenyl)phenyl, —(CH 2 )-(2-alkynyl)phenyl, —(CH 2 )-(3-alkynyl)phenyl, —(CH 2 )-(2-nitro)phenyl, —(CH 2 )-(3-nitro)phenyl, —(CH 2 )-(2-carboxy)phenyl, —(CH 2 )-(3-carboxy)phenyl, —(CH 2 )-(2-carboxamido)phenyl, —(CH 2
  • R 2 is selected from the group consisting of 3-amino-piperidin-1-yl, 3-aminomethyl-pyrrolidin-1-yl, azetidin-1-yl, 3-aminoazetidin-1-yl, pyrrolidin-1-yl, 3-aminocyclopent-1-yl, 3-aminomethylcyclopent-1-yl, 3-aminomethylcyclohex-1-yl, hexahydroazepin-1-yl, 3-aminohexahydroazepin-1-yl, 3-amino-cyclohex-1-yl, piperazin-1-yl, homopiperazin-1-yl, 3-amino-pyrrolidin-1-yl, and R-3-aminopiperidin-1-yl, each substituted or unsubstituted.
  • R 1 is selected from the group consisting of —(CH 2 )-(2-cyano)phenyl, —(CH 2 )-(3-cyano)phenyl, —(CH 2 )-(2-hydroxy)phenyl, —(CH 2 )-(3-hydroxy)phenyl, —(CH 2 )-(2-alkenyl)phenyl, —(CH 2 )-(3-alkenyl)phenyl, —(CH 2 )-(2-alkynyl)phenyl, —(CH 2 )-(3-alknyl)phenyl, —(CH 2 )-(2-nitro)phenyl, —(CH 2 )-(3-nitro)phenyl, —(CH 2 )-(2-carboxy)phenyl, —(CH 2 )-(3-carboxy)phenyl, —(CH 2 )-(2-carboxamido)phenyl, —(CH 2
  • R 2 is selected from the group consisting of 3-amino-piperidin-1-yl, 3-aminomethyl-pyrrolidin-1-yl, azetidin-1-yl, 3-aminoazetidin-1-yl, pyrrolidin-1-yl, 3-aminocyclopent-1-yl, 3-aminomethylcyclopent-1-yl, 3-aminomethylcyclohex-1-yl, hexahydroazepin-1-yl, 3-aminohexahydroazepin-1-yl, 3-amino-cyclohex-1-yl, piperazin-1-yl, homopiperazin-1-yl, 3-amino-pyrrolidin-1-yl, and R-3-aminopiperidin-1-yl, each substituted or unsubstituted.
  • R 1 is selected from the group consisting of —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —NHC 1-3 -alkyl, and —N(C 1-3 -alkyl) 2 each unsubstituted or substituted through available valencies, and
  • R 2 is selected from the group consisting of 3-amino-piperidin-1-yl, 3-aninomethyl-pyrrolidin-1-yl, azetidin-1-yl, 3-aminoazetidin-1-yl, pyrrolidin-1-yl, 3-aminocyclopent-1-yl, 3-aminomethylcyclopent-1-yl, 3-aminomethylcyclohex-1-yl, hexahydroazepin-1-yl, 3-aminohexahydroazepin-1-yl, 3-amino-cyclohex-1-yl, piperazin-1-yl, homopiperazin-1-yl, 3-amino-pyrrolidin-1-yl, and R-3-aminopiperidin-1-yl, each substituted or unsubstituted.
  • R 1 is selected from the group consisting of —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —NHC 1-3 -allyl, and —N(C 1-3 -alkyl) 2 each unsubstituted or substituted through available valencies, and
  • R 2 is selected from the group consisting of 3-amino-piperidin-1-yl, 3-aminomethyl-pyrrolidin-1-yl, azetidin-1-yl, 3-amninoazetidin-1-yl, pyrrolidin-1-yl, 3-aminocyclopent-1-yl, 3-aminomethylcyclopent-1-yl, 3-aminomethylcyclohex-1-yl, hexahydroazepin-1-yl, 3-aminohexahydroazepin-1-yl, 3-amino-cyclohex-1-yl, piperazin-1-yl, homopiperazin-1-yl, 3-amino-pyrrolidin-1-yl, and R-3-aminopiperidin-1-yl, each substituted or unsubstituted.
  • R 1 is selected from the group consisting of —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —NHC 1-3 -alkyl, and —N(C 1-3 -alkyl) 2 each unsubstituted or substituted through available valencies, and
  • R 2 is selected from the group consisting of 3-amino-piperidin-1-yl, 3-aminomethyl-pyrrolidin-1-yl, azetidin-1-yl, 3-aminoazetidin-1-yl, pyrrolidin-1-yl, 3-aminocyclopent-1-yl, 3-aminomethylcyclopent-1-yl, 3-aminomethylcyclohex-1-yl, hexahydroazepin-1-yl, 3-aminohexahydroazepin-1-yl, 3-amino-cyclohex-1-yl, piperazin-1-yl, homopiperazin-1-yl, 3-amino-pyrrolidin-l-yl, and R-3-aminopiperidin- l-yl, each substituted or unsubstituted.
  • DPP-IV inhibitors include:
  • the present invention provides the compounds in the form of a pharmaceutically acceptable salt.
  • the present invention provides the compounds present in a mixture of stereoisomers. In yet another embodiment, the present invention provides the compounds as a single stereoisomer.
  • the present invention provides pharmaceutical compositions comprising the compound as an active ingredient.
  • the present invention provides pharmaceutical compositions wherein the composition is a solid formulation adapted for oral administration.
  • the present invention provides pharmaceutical composition wherein the composition is a tablet.
  • the present invention provides the pharmaceutical composition wherein the composition is a liquid formulation adapted for oral administration.
  • the present invention provides pharmaceutical composition wherein the composition is a liquid formulation adapted for parenteral administration.
  • the present invention provides the pharmaceutical composition comprising the compound of the invention wherein the composition is adapted for administration by a route selected from the group consisting of orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intrarrticularly, and intrathecally.
  • the present invention provides a kit comprising a compound of the present invention and instructions which comprise one or more forms of information selected from the group consisting of indicating a disease state for which the compound is to be administered, storage information for the compound, dosing information and instructions regarding how to administer the compound.
  • the present invention provides the kit that comprises the compound in a multiple dose form.
  • the present invention provides an article of manufacture comprising a compound of the present invention, and packaging materials.
  • the packaging material comprises a container for housing the compound.
  • the invention provides the article of manufacture wherein the container comprises a label indicating one or more members of the group consisting of a disease state for which the compound is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition.
  • the present invention provides the article of manufacture wherein the article of manufacture comprises the compound in a multiple dose form.
  • the present invention provides a method of inhibiting DPP-IV comprising contacting DPP-IV with a compound according to the present invention.
  • the present invention provides a method of inhibiting DPP-IV comprising causing a compound according to the present invention to be present in a subject in order to inhibit DPP-WV in vivo.
  • the present invention provides a method of inhibiting DPP-IV comprising: administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits DPP-IV in vivo, the second compound being a compound of the present invention.
  • the present invention provides therapeutic method comprising: administering a compound according to the present invention to a subject.
  • the present invention provides a method of treating a disease state for which DPP-IV possesses activity that contributes to the pathology and/or symptomology of the disease state, the method comprising causing a compound of the present invention to be present in a subject in a therapeutically effective amount for the disease state.
  • the present invention provides a method of treating cancer in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to the present invention.
  • the present invention provides a method of treating a disease where the disease is type I or type II diabetes.
  • the present invention provides a method of treating autoimmune disorders such as, but not limited to, rheumatoid arthritis, psoriasis, and multiple sclerosis in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to the present invention.
  • the present invention provides a method of treating cancer where the cancer treated is colorectal, prostate, breast, thyroid, skin, lung, or head and neck.
  • the present invention provides a method of treating a condition characterized by inadequate lymphocyte or hemapoietic cell activation or concentration in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to the present invention.
  • the present invention provides a method of treating HV infection in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to the present invention.
  • the present invention provides a method of treating a condition characterized by inadequate lymphocyte or hemapoietic cell activation or concentration in a patient in need thereof, wherein the condition is a side effect of chemotherapy or radiation therapy.
  • the present invention provides a method of treating a condition characterized by inadequate lymphocyte or hemapoietic cell activation or concentration in a patient in need thereof, wherein the condition is a result of kidney failure.
  • the present invention provides a method of treating a condition characterized by inadequate lymphocyte or hemapoietic cell activation or concentration in a patient in need thereof, wherein the condition is a result of a bone marrow disorder.
  • the present invention provides a method of treating a condition characterized by immunodeficiency symptoms in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to the present invention.
  • the compounds of the present invention may be present and optionally administered in the form of salts, hydrates and prodrugs that are converted in vivo into the compounds of the present invention.
  • the compounds of the present invention possess a free base form
  • the compounds can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, e.g., hydrohalides such as hydrochloride, hydrobromide, hydroiodide; other mineral acids and their corresponding salts such as sulfate, nitrate, phosphate, etc.; and alkyl and monoarylsulfonates such as ethanesulfonate, toluenesulfonate and benzenesulfonate; and other organic acids and their corresponding salts such as acetate, tartrate, maleate, succinate, citrate, benzoate, salicylate and ascorbate.
  • a pharmaceutically acceptable inorganic or organic acid e.g., hydrohalides such as hydrochloride, hydrobromide, hydroiodide
  • other mineral acids and their corresponding salts such as sulfate, n
  • Further acid addition salts of the present invention include, but are not limited to: adipate, alginate, arginate, aspartate, bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, cyclopentanepropionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptaoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, iso-butyrate, lactate, lactobionate, malate, malonate, man
  • a pharmaceutically acceptable base addition salt can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base.
  • bases include alkali metal hydroxides including potassium, sodium and lithium hydroxides; alkaline earth metal hydroxides such as barium and calcium hydroxides; alkali metal alkoxides, e.g. potassium ethanolate and sodium propanolate; and various organic bases such as ammonium hydroxide, piperidine, diethanolamine and N-methylglutamine.
  • aluminum salts of the compounds of the present invention are alkali metal hydroxides including potassium, sodium and lithium hydroxides; alkaline earth metal hydroxides such as barium and calcium hydroxides; alkali metal alkoxides, e.g. potassium ethanolate and sodium propanolate; and various organic bases such as ammonium hydroxide, piperidine, diethanolamine and N-methylglutamine.
  • aluminum salts of the compounds of the present invention are also included.
  • Organic base salts of the present invention include, but are not limited to: copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium and zinc salts.
  • Organic base salts include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, e.g., arginine, betaine, caffeine, chloroprocaine, choline, N,N′-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, iso-propylamine, lidocaine, lysine, meglumine, N
  • Compounds of the present invention that comprise basic nitrogen-containing groups may be quaternized with such agents as (C 1-4 )alkyl halides, e.g., methyl, ethyl, iso-propyl and tert-butyl chlorides, bromides and iodides; di (C 1-4 )alkyl sulfates, e.g., dimethyl, diethyl and diamyl sulfates; (C 10-18 )alkyl halides, e.g., decyl, dodecyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; and aryl (C 1-4 )alkyl halides, e.g., benzyl chloride and phenethyl bromide.
  • Such salts permit the preparation of both water-soluble and oil-soluble compounds of the present invention.
  • N-oxides of compounds according to the present invention can be prepared by methods known to those of ordinary skill in the art.
  • N-oxides can be prepared by treating an unoxidized form of the compound with an oxidizing agent (e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like) in a suitable inert organic solvent (e.g., a halogenated hydrocarbon such as dichloromethane) at approximately 0 OC.
  • an oxidizing agent e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like
  • a suitable inert organic solvent e.g., a halogenated hydrocarbon such as dichloromethane
  • Prodrug derivatives of compounds according to the present invention can be prepared by modifying substituents of compounds of the present invention that are then converted in vivo to a different substituent. It is noted that in many instances, the prodrugs themselves also fall within the scope of the range of compounds according to the present invention.
  • prodrugs can be prepared by reacting a compound with a carbamylating agent (e.g., 1,1-acyloxyalkylcarbonochloridate, para-nitrophenyl carbonate, or the like) or an acylating agent. Further examples of methods of making prodrugs are described in Saulnier et al.(1994), Bioorganic and Medicinal Chemistry Letters , Vol. 4, p. 1985.
  • Hydrates of compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.
  • a “pharmaceutically acceptable salt”, as used herein, is intended to encompass any compound according to the present invention that is utilized in the form of a salt thereof, especially where the salt confers on the compound improved pharmacokinetic properties as compared to the free form of compound or a different salt form of the compound.
  • the pharmaceutically acceptable salt form may also initially confer desirable pharmacokinetic properties on the compound that it did not previously possess, and may even positively affect the pharmacodynamics of the compound with respect to its therapeutic activity in the body.
  • An example of a pharmacokinetic property that may be favorably affected is the manner in which the compound is transported across cell membranes, which in turn may directly and positively affect the absorption, distribution, biotransformation and excretion of the compound.
  • the solubility of the compound is usually dependent upon the character of the particular salt form thereof, which it utilized.
  • an aqueous solution of the compound will provide the most rapid absorption of the compound into the body of a subject being treated, while lipid solutions and suspensions, as well as solid dosage forms, will result in less rapid adsorption of the compound.
  • DPP-IV is believed to contribute to the pathology and/or symptomology of several different diseases such that reduction of the activity of DPP-IV in a subject through inhibition may be used to therapeutically address these disease states. Examples of various diseases that may be treated using the DPP-IV inhibitors of the present invention are described herein. It is noted that additional diseases beyond those disclosed herein may be later identified as the biological roles that DPP-IV plays in various pathways becomes more fully understood.
  • DPP-IV inhibitors of the present invention may be used to treat are those involving the prevention and treatment of diabetes and obesity, in particular type 2 diabetes mellitus, diabetic dislipidemia, conditions of impaired glucose tolerance (IGf), conditions of impaired fasting plasma glucose (IFG), metabolic acidosis, ketosis, appetite regulation and obesity.
  • type 2 diabetes mellitus in particular type 2 diabetes mellitus, diabetic dislipidemia, conditions of impaired glucose tolerance (IGf), conditions of impaired fasting plasma glucose (IFG), metabolic acidosis, ketosis, appetite regulation and obesity.
  • DPP-IV inhibitors of the present invention may also be used as immunosuppressants (or cytokine release suppressant drugs) for the treatment of among other things: organ transplant rejection; autoimmune diseases such as inflammatory bowel disease, multiple sclerosis and rheumatoid arthritis; and the treatment of AIDS.
  • immunosuppressants or cytokine release suppressant drugs
  • DPP-IV inhibitors of the present invention may also be used for treating various cancers including breast cancer, lung cancer and prostate cancer.
  • DPP-IV inhibitors of the present invention may also be used to treat dermatological diseases such as psoriasis, rheumatoid arthritis (RA) and lichen planus.
  • dermatological diseases such as psoriasis, rheumatoid arthritis (RA) and lichen planus.
  • DPP-IV inhibitors of the present invention may also be used to treat infertility and amenorrhea.
  • DPP-IV inhibitors of the present invention may also be used to modulate cleavage of various cytokines (stimulating hematopoietic cells), growth factors and neuropeptides. For example, such conditions occur frequently in patients who are immunosuppressed, for example, as a consequence of chemotherapy and/or radiation therapy for cancer.
  • DPP-IV inhibitors of the present invention may also be used prevent or reduce cleavage of N-term-inal Tyr-Ala from growth hormone-releasing factor. Accordingly, these inhibitors maybe used in the treatment of short stature due to growth hormone deficiency (Dwarfism) and for promoting GH-dependent tissue growth or re-growth.
  • Dwarfism growth hormone deficiency
  • DPP-IV inhibitors of the present invention may also be used to address disease states associated with cleavage of neuropeptides and thus may be useful for the regulation or normalization of neurological disorders.
  • DPP-IV inhibitors of the present invention may be used in conjunction with other agents to inhibit undesirable and uncontrolled cell proliferation.
  • examples of other anti-cell proliferation agents include, but are not limited to, retinoid acid and derivatives thereof, 2-methoxyestradiol, ANGIOSTATIN protein, ENDOSTATINTM protein, suramin, squalamine, tissue inhibitor of metalloproteinase-I, tissue inhibitor of metalloproteinase-2, plasminogen activator inhibitor-1, plasminogen activator inhibitor-2, cartilage-derived inhibitor, paclitaxel, platelet factor 4, protamine sulfate (clupeine), sulfated chitin derivatives (prepared from queen crab shells), sulfated polysaccharide peptidoglycan complex (sp-pg), staurosporine, modulators of matrix metabolism, including for example, proline analogs ((1-
  • anti-angiogenesis agents include antibodies, preferably monoclonal antibodies against these angiogenic growth factors: bFGF, aFGF, FGF-5, VEGF isoforms, VEGF-C, HGF/SF and Ang-1/Ang-2.
  • bFGF vascular endothelial growth factor
  • FGF-5 vascular endothelial growth factor
  • VEGF isoforms VEGF-C
  • HGF/SF Ang-1/Ang-2.
  • compositions and administration methods may be used in conjunction with the DPP-IV inhibitors of the present invention.
  • Such compositions may include, in addition to the DPP-WV inhibitors of the present invention, conventional pharmaceutical excipients, and other conventional, pharmaceutically inactive agents.
  • the compositions may include active agents in addition to the DPP-IV inhibitors of the present invention.
  • These additional active agents may include additional compounds according to the invention, and/or one or more other pharmaceutically active agents.
  • compositions may be in gaseous, liquid, semi-liquid or solid form, formulated in a manner suitable for the route of administration to be used.
  • routes of administration for oral administration, capsules and tablets are typically used.
  • parenteral administration reconstitution of a lyophilized powder, prepared as described herein, is typically used.
  • compositions comprising DPP-IV inhibitors of the present invention may be administered or coadministered orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, or intrathecally.
  • the compounds and/or compositions according to the invention may also be administered or coadministered in slow release dosage forms.
  • the DPP-IV inhibitors and compositions comprising them may be administered or coadministered in any conventional dosage form.
  • Co-administration in the context of this invention is intended to mean the administration of more than one therapeutic agent, one of which includes a DPP-IV inhibitor, in the course of a coordinated treatment to achieve an improved clinical outcome.
  • Such co-administration may also be coextensive, that is, occurring during overlapping periods of time.
  • Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application may optionally include one or more of the following components: a sterile diluent, such as water for injection, saline solution, fixed oil, polyethylene glycol, glycerine, propylene glycol or other synthetic solvent; antimicrobial agents, such as benzyl alcohol and methyl parabens; antioxidants, such as ascorbic acid and sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid (EDTA); buffers, such as acetates, citrates and phosphates; agents for the adjustment of tonicity such as sodium chloride or dextrose, and agents for adjusting the acidity or alkalinity of the composition, such as alkaline or acidifying agents or buffers like carbonates, bicarbonates, phosphates, hydrochloric acid, and organic acids like acetic and citric acid.
  • Parenteral preparations may optionally be enclosed in ampules
  • DPP-IV inhibitors according to the present invention exhibit insufficient solubility
  • methods for solubilizing the compounds include, but are not limited to, using cosolvents, such as dimethylsulfoxide (DMSO), using surfactants, such as TWEEN, or dissolution in aqueous sodium bicarbonate.
  • cosolvents such as dimethylsulfoxide (DMSO)
  • surfactants such as TWEEN
  • dissolution in aqueous sodium bicarbonate such as sodium bicarbonate
  • Derivatives of the compounds, such as prodrugs of the compounds may also be used in formulating effective pharmaceutical compositions.
  • a solution, suspension, emulsion or the like may be formed.
  • the form of the resulting composition will depend upon a number of factors, including the intended mode of administration, and the solubility of the compound in the selected carrier or vehicle.
  • the effective concentration needed to ameliorate the disease being treated may be empirically determined.
  • compositions according to the present invention are optionally provided for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, dry powders for inhalers, granules, sterile parenteral solutions or suspensions, and oral solutions or suspensions, and oil-water emulsions containing suitable quantities of the compounds, particularly the pharmaceutically acceptable salts, preferably the sodium salts, thereof.
  • the pharmaceutically therapeutically active compounds and derivatives thereof are typically formulated and administered in unit-dosage forms or multiple-dosage forms.
  • Unit-dose forms refers to physically discrete units suitable for human and animal subjects and packaged individually as is known in the art.
  • Each unit-dose contains a predetermined quantity of the therapeutically active compound sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carrier, vehicle or diluent.
  • unit-dose forms include ampoules and syringes individually packaged tablet or capsule.
  • Unit-dose forms may be administered in fractions or multiples thereof.
  • a multiple-dose form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dose form.
  • Examples of multiple-dose forms include vials, bottles of tablets or capsules or bottles of pint or gallons.
  • multiple dose form is a multiple of unit-doses that are not segregated in packaging.
  • the composition may comprise: a diluent such as lactose, sucrose, dicalcium phosphate, or carboxymethylcellulose; a lubricant, such as magnesium stearate, calcium stearate and talc; and a binder such as starch, natural gums, such as gum acaciagelatin, glucose, molasses, polvinylpyrrolidine, celluloses and derivatives thereof, povidone, crospovidones and other such binders known to those of skill in the art.
  • a diluent such as lactose, sucrose, dicalcium phosphate, or carboxymethylcellulose
  • a lubricant such as magnesium stearate, calcium stearate and talc
  • a binder such as starch, natural gums, such as gum acaciagelatin, glucose, molasses, polvinylpyrrolidine, celluloses and derivatives thereof, povidone, crospovidones and other such binders
  • Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, or otherwise mixing an active compound as defmed above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like, to form a solution or suspension.
  • a carrier such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like
  • the pharmaceutical composition to be administered may also contain minor amounts of auxiliary substances such as wetting agents, emulsifying agents, or solubilizing agents, pH buffering agents and the like, for example, acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and other such agents.
  • composition or formulation to be administered will, in any event, contain a sufficient quantity of a DPP-IV inhibitor of the present invention to reduce DPP-IV activity in vivo, thereby treating the disease state of the subject.
  • Dosage forms or compositions may optionally comprise one or more DPP-IV inhibitors according to the present invention in the range of 0.005% to 100% (weight/weight) with the balance comprising additional substances such as those described herein.
  • a pharmaceutically acceptable composition may optionally comprise any one or more commonly employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, talcum, cellulose derivatives, sodium crosscarmellose, glucose, sucrose, magnesium carbonate, sodium saccharin, talcum.
  • compositions include solutions, suspensions, tablets, capsules, powders, dry powders for inhalers and sustained release formulations, such as, but not limited to, implants and microencapsulated delivery systems, and biodegradable, biocompatible polymers, such as collagen, ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and others. Methods for preparing these formulations are known to those skilled in the art.
  • the compositions may optionally contain 0.01%-100% (weightiweight) of one or more DPP-IV inhibitors, optionally 0.1-95%, and optionally 1-95%.
  • Salts, preferably sodium salts, of the DPP-IV inhibitors may be prepared with carriers that protect the compound against rapid elimination from the body, such as time release formulations or coatings.
  • the formulations may further include other active compounds to obtain desired combinations of properties.
  • Oral pharmaceutical dosage forms may be as a solid, gel or liquid.
  • solid dosage forms include, but are not limited to tablets, capsules, granules, and bulk powders. More specific examples of oral tablets include compressed, chewable lozenges and tablets that may be enteric-coated, sugar-coated or film-coated.
  • capsules include hard or soft gelatin capsules. Granules and powders may be provided in non-effervescent or effervescent forms. Each may be combined with other ingredients known to those skilled in the art.
  • DPP-IV inhibitors according to the present invention are provided as solid dosage forms, preferably capsules or tablets.
  • the tablets, pills, capsules, troches and the like may optionally contain one or more of the following ingredients, or compounds of a similar nature: a binder; a diluent; a disintegrating agent; a lubricant; a glidant; a sweetening agent; and a flavoring agent.
  • binders examples include, but are not limited to, microcrystalline cellulose, gum tragacanth, glucose solution, acacia mucilage, gelatin solution, sucrose and starch paste.
  • lubricants examples include, but are not limited to, talc, starch, magnesium or calcium stearate, lycopodium and stearic acid.
  • diluents examples include, but are not limited to, lactose, sucrose, starch, kaolin, salt, mannitol and dicalcium phosphate.
  • glidants examples include, but are not limited to, colloidal silicon dioxide.
  • disintegrating agents examples include, but are not limited to, crosscarmellose sodium, sodium starch glycolate, alginic acid, corn starch, potato starch, bentonite, methylcellulose, agar and carboxymethylcellulose.
  • coloring agents examples include, but are not limited to, any of the approved certified water soluble FD and C dyes, mixtures thereof; and water insoluble FD and C dyes suspended on alumina hydrate.
  • sweetening agents examples include, but are not limited to, sucrose, lactose, mannitol and artificial sweetening agents such as sodium cyclamate and saccharin, and any number of spray-dried flavors.
  • flavoring agents examples include, but are not limited to, natural flavors extracted from plants such as fruits and synthetic blends of compounds that produce a pleasant sensation, such as, but not limited to peppermint and methyl salicylate.
  • wetting agents examples include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether.
  • anti-emetic coatings examples include, but are not limited to, fatty acids, fats, waxes, shellac, ammoniated shellac and cellulose acetate phthalates.
  • film coatings examples include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000 and cellulose acetate phthalate.
  • the salt of the compound may optionally be provided in a composition that protects it from the acidic environment of the stomach.
  • the composition can be formulated in an enteric coating that maintains its integrity in the stomach and releases the active compound in the intestine.
  • the composition may also be formulated in combination with an antacid or other such ingredient.
  • dosage unit form When the dosage unit form is a capsule, it may optionally additionally comprise a liquid carrier such as a fatty oil. In addition, dosage unit forms may optionally additionally comprise various other materials that modify the physical form of the dosage unit, for example, coatings of sugar and other enteric agents.
  • Compounds according to the present invention may also be administered as a component of an elixir, suspension, syrup, wafer, sprinkle, chewing gum or the like.
  • a syrup may optionally comprise, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
  • the DPP-IV inhibitors of the present invention may also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antacids, H2 blockers, and diuretics.
  • active materials such as antacids, H2 blockers, and diuretics.
  • Examples of pharmaceutically acceptable carriers that may be included in tablets comprising DPP-IV inhibitors of the present invention include, but are not limited to binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, and wetting agents.
  • Enteric-coated tablets because of the enteric-coating, resist the action of stomach acid and dissolve or disintegrate in the neutral or alkaline intestines.
  • Sugar-coated tablets may be compressed tablets to which different layers of pharmaceutically acceptable substances are applied.
  • Film-coated tablets may be compressed tablets that have been coated with polymers or other suitable coating. Multiple compressed tablets may be compressed tablets made by more than one compression cycle utilizing the pharmaceutically acceptable substances previously mentioned.
  • Coloring agents may also be used in tablets. Flavoring and sweetening agents may be used in tablets, and are especially useful in the formation of chewable tablets and lozenges.
  • liquid oral dosage forms examples include, but are not limited to, aqueous solutions, emulsions, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules.
  • aqueous solutions examples include, but are not limited to, elixirs and syrups.
  • elixirs refer to clear, sweetened, hydroalcoholic preparations.
  • pharmaceutically acceptable carriers examples include, but are not limited to solvents.
  • solvents Particular examples include glycerin, sorbitol, ethyl alcohol and syrup.
  • syrups refer to concentrated aqueous solutions of a sugar, for example, sucrose. Syrups may optionally further comprise a preservative.
  • Emulsions refer to two-phase systems in which one liquid is dispersed in the form of small globules throughout another liquid. Emulsions may optionally be oil-in-water or water-in-oil emulsions. Examples of pharmaceutically acceptable carriers that may be used in emulsions include, but are not limited to non-aqueous liquids, emulsifying agents and preservatives.
  • Examples of pharmaceutically acceptable substances that may be used in non-effervescent granules, to be reconstituted into a liquid oral dosage form, include diluents, sweeteners and wetting agents.
  • Examples of pharmaceutically acceptable substances that may be used in effervescent granules, to be reconstituted into a liquid oral dosage form, include organic adds and a source of carbon dioxide.
  • Coloring and flavoring agents may optionally be used in all of the above dosage forms.
  • preservatives include glycerin, methyl and propylparaben, benzoic add, sodium benzoate and alcohol.
  • emulsifying agents include gelatin, acacia, tragacanth, bentonite, and surfactants such as polyoxyethylene sorbitan monooleate.
  • suspending agents include sodium carboxymethylcellulose, pectin, tragacanth, Veegum and acacia.
  • Diluents include lactose and sucrose.
  • Sweetening agents include sucrose, syrups, glycerin and artificial sweetening agents such as sodium cyclamate and saccharin.
  • wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether.
  • organic acids that may be used include citric and tartaric acid.
  • Sources of carbon dioxide that maybe used in effervescent compositions include sodium bicarbonate and sodium carbonate.
  • Coloring agents include any of the approved certified water soluble FD and C dyes, and mixtures thereof.
  • flavoring agents include natural flavors extracted from plants such fruits, and synthetic blends of compounds that produce a pleasant taste sensation.
  • the solution or suspension in for example propylene carbonate, vegetable oils or triglycerides, is preferably encapsulated in a gelatin capsule.
  • a gelatin capsule Such solutions, and the preparation and encapsulation thereof, are disclosed in U.S. Pat. Nos. 4,328,245; 4,409,239; and 4,410,545.
  • the solution e.g., for example, in a polyethylene glycol, maybe diluted with a sufficient quantity of a pharmaceutically acceptable liquid carrier, e.g. water, to be easily measured for administration.
  • liquid or semi-solid oral formulations may be prepared by dissolving or dispersing the active compound or salt in vegetable oils, glycols, triglycerides, propylene glycol esters (e.g. propylene carbonate) and other such carriers, and encapsulating these solutions or suspensions in hard or soft gelatin capsule shells.
  • Other useful formulations include those set forth in U.S. Pat. Nos. Re 28,819 and 4,358,603.
  • compositions designed to administer the DPP-IV inhibitors of the present invention by parenteral adrninistration generally characterized by injection, either subcutaneously, intramuscularly or intravenously.
  • injectables may be prepared in any conventional form, for example as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
  • excipients examples include, but are not limited to water, saline, dextrose, glycerol or ethanol.
  • the injectable compositions may also optionally comprise minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, and other such agents, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins.
  • Implantation of a slow-release or sustained-release system such that a constant level of dosage is maintained (see, e.g., U.S. Pat. No. 3,710,795) is also contemplated herein.
  • the percentage of active compound contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject.
  • Parenteral administration of the formulations includes intravenous, subcutaneous and intramuscular administrations.
  • Preparations for parenteral administration include sterile solutions ready for injection, sterile dry soluble products, such as the lyophilized powders described herein, ready to be combined with a solvent just prior to use, including hypodermic tablets, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a.vehicle just prior to use and sterile emulsions.
  • the solutions may be either aqueous or nonaqueous.
  • suitable carriers include, but are not limited to physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.
  • PBS physiological saline or phosphate buffered saline
  • Examples of pharmaceutically acceptable carriers that may optionally be used in parenteral preparations include, but are not limited to aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents and other pharmaceutically acceptable substances.
  • aqueous vehicles examples include Sodium Chloride Injection, Ringers Injection, Isotonic Dextrose Injection, Sterile Water Injection, Dextrose and Lactated Ringers Injection.
  • nonaqueous parenteral vehicles examples include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil and peanut oil.
  • Antimicrobial agents in bacteriostatic or fungistatic concentrations may be added to parenteral preparations, particularly when the preparations are packaged in multiple-dose containers and thus designed to be stored and multiple aliquots to be removed.
  • antimicrobial agents include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride and benzethonium chloride.
  • Examples of isotonic agents that may be used include sodium chloride and dextrose.
  • Examples of buffers that may be used include phosphate and citrate.
  • antioxidants that may be used include sodium bisulfate.
  • Examples of local anesthetics that may be used include procaine hydrochloride.
  • Examples of suspending and dispersing agents that may be used include sodium carboxymethylcellulose, hydroxypropyl methylcellulose and polyvinylpyrrolidone.
  • Examples of emulsifying agents that may be used include Polysorbate 80 (TWEEN 80).
  • a sequestering or chelating agent of metal ions include EDTA.
  • Pharmaceutical carriers may also optionally include ethyl alcohol, polyethylene glycol and propylene glycol for water miscible vehicles and sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment.
  • the concentration of a DPP-IV inhibitor in the parenteral formulation may be adjusted so that an injection administers a pharmaceutically effective amount sufficient to produce the desired pharmacological effect.
  • concentration of a DPP-IV inhibitor and/or dosage to be used will ultimately depend on the age, weight and condition of the patient or animal as is known in the art.
  • Unit-dose parenteral preparations may be packaged in an ampoule, a vial or a syringe with a needle. All preparations for parenteral administration should be sterile, as is know and practiced in the art.
  • Injectables may be designed for local and systemic administration. Typically a therapeutically effective dosage is formulated to contain a concentration of at least about 0.1% w/w up to about 90% w/w or more, preferably more than 1% w/w of the DPP-IV inhibitor to the treated tissue(s).
  • the DPP-IV inhibitor may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment will be a function of the location of where the composition is parenterally administered, the carrier and other variables that may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data.
  • concentrations and dosage values may also vary with the age of the individual treated. It is to be further understood that for any particular subject, specific dosage regimens may need to be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations. Hence, the concentration ranges set forth herein are intended to be exemplary and are not intended to limit the scope or practice of the claimed formulations.
  • the DPP-IV inhibitor may optionally be suspended in micronized or other suitable form or may be derivatized to produce a more soluble active product or to produce a prodrug.
  • the form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the selected carrier or vehicle.
  • the effective concentration is sufficient for ameliorating the symptoms of the disease state and may be empirically determined.
  • the DPP-IV inhibitors of the present invention may also be prepared as lyophilized powders, which can be reconstituted for administration as solutions, emulsions and other mixtures.
  • the lyophilized powders may also be formulated as solids or gels.
  • Sterile, lyophilized powder may be prepared by dissolving the compound in a sodium phosphate buffer solution containing dextrose or other suitable excipient. Subsequent sterile filtration of the solution followed by lyophilization under standard conditions known to those of skill in the art provides the desired formulation. Briefly, the lyophilized powder may optionally be prepared by dissolving dextrose, sorbitol, fructose, corn syrup, xylitol, glycerin, glucose, sucrose or other suitable agent, about 1-20%, preferably about 5 to 15%, in a suitable buffer, such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the art at, typically, about neutral pH.
  • a suitable buffer such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the art at, typically, about neutral pH.
  • a DPP-IV inhibitor is added to the resulting mixture, preferably above room temperature, more preferably at about 30-35 ° C., and stirred until it dissolves.
  • the resulting mixture is diluted by adding more buffer to a desired concentration.
  • the resulting mixture is sterile filtered or treated to remove particulates and to insure sterility, and apportioned into vials for lyophilization. Each vial may contain a single dosage or multiple dosages of the DPP-IV inhibitor.
  • the DPP-IV inhibitors of the present invention may also be administered as topical mixtures.
  • Topical mixtures may be used for local and systemic administration.
  • the resulting mixture may be a solution, suspension, emulsions or the like and are formulated as creams, gels, ointments, emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, irrigations, sprays, suppositories, bandages, dermal patches or any other formulations suitable for topical administration.
  • the DPP-IV inhibitors may be formulated as aerosols for topical application, such as by inhalation (see, U.S. Pat. Nos. 4,044,126, 4,414,209, and 4,364,923, which describe aerosols for delivery of a steroid useful for treatment inflammatory diseases, particularly asthma).
  • These formulations for administration to the respiratory tract can be in the form of an aerosol or solution for a nebulizer, or as a microfme powder for insufflation, alone or in combination with an inert carrier such as lactose.
  • the particles of the formulation will typically have diameters of less than 50 microns, preferably less than 10 microns.
  • the DPP-IV inhibitors may also be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye or for intracisternal or intraspinal application. Topical administration is contemplated for transdermal delivery and also for administration to the eyes or mucosa, or for inhalation therapies. Nasal solutions of the DPP-IV inhibitor alone or in combination with other pharmaceutically acceptable excipients can also be administered.
  • rectal administration may also be used.
  • pharmaceutical dosage forms for rectal administration are rectal suppositories, capsules and tablets for systemic effect.
  • Rectal suppositories are used herein mean solid bodies for insertion into the rectum that melt or soften at body temperature releasing one or more pharmacologically or therapeutically active ingredients.
  • Pharmaceutically acceptable substances utilized in rectal suppositories are bases or vehicles and agents to raise the melting point.
  • bases examples include cocoa butter (theobroma oil), glycerin-gelatin, carbowax, (polyoxyethylene glycol) and appropriate mixtures of mono-, di- and triglycerides of fatty acids. Combinations of the various bases may be used.
  • Agents to raise the melting point of suppositories include spermaceti and wax. Rectal suppositories may be prepared either by the compressed method or by molding. The typical weight of a rectal suppository is about 2 to 3 gm. Tablets and capsules for rectal administration may be manufactured using the same pharmaceutically acceptable substance and by the same methods as for formulations for oral administration.
  • the invention is also directed to kits and other articles of manufacture for treating diseases associated with DPP-IV. It is noted that diseases are intended to cover all conditions for which the DPP-IV possesses activity that contributes to the pathology and/or symptomology of the condition.
  • a kit comprising a composition comprising at least one DPP-IV inhibitor of the present invention in combination with instructions.
  • the instructions may indicate the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition.
  • the kit may also comprise packaging materials.
  • the packaging material may comprise a container for housing the composition.
  • the kit may also optionally comprise additional components, such as syringes for administration of the composition.
  • the kit may comprise the composition in single or multiple dose forms.
  • an article of manufacture comprises a composition comprising at least one DPP-IV inhibitor of the present invention in combination with packaging materials.
  • the packaging material may comprise a container for housing the composition.
  • the container may optionally comprise a label indicating the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition.
  • the kit may also optionally comprise additional components, such as syringes for administration of the composition.
  • the kit may comprise the composition in single or multiple dose forms.
  • the packaging material used in kits and articles of manufacture according to the present invention may form a plurality of divided containers such as a divided bottle or a divided foil packet.
  • the container can be in any conventional shape or form as known in the art which is made of a pharmaceutically acceptable material, for example a paper or cardboard box, a glass or plastic bottle orjar, a re-sealable bag (for example, to hold a “refill” of tablets for placement into a different container), or a blister pack with individual doses for pressing out of the pack according to a therapeutic schedule.
  • the container that is employed will depend on the exact dosage form involved, for example a conventional cardboard box would not generally be used to hold a liquid suspension.
  • kits can be used together in a single package to market a single dosage form.
  • tablets may be contained in a bottle that is in turn contained within a box.
  • the kit includes directions for the administration of the separate components.
  • the kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral, topical, transdermal and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.
  • Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process recesses are formed in the plastic foil. The recesses have the size and shape of individual tablets or capsules to be packed or may have the size and shape to accommodate multiple tablets and/or capsules to be packed. Next, the tablets or capsules are placed in the recesses accordingly and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed.
  • the tablets or capsules are individually sealed or collectively sealed, as desired, in the recesses between the plastic foil and the sheet.
  • the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.
  • kits are a dispenser designed to dispense the daily doses one at a time in the order of their intended use.
  • the dispenser is equipped with a memory-aid, so as to further facilitate compliance with the regimen.
  • a memory-aid is a mechanical counter that indicates the number of daily doses that has been dispensed.
  • a battery-powered micro-chip memory coupled with a liquid crystal readout, or audible reminder signal which, for example, reads out the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken.
  • a racemic mixture of a compound may be reacted with an optically active resolving agent to form a pair of diastereoisomeric compounds.
  • the diastereomers may then be separated in order to recover the optically pure enantiomers.
  • Dissociable complexes may also be used to resolve enantiomers (e.g., crystalline diastereoisomeric salts).
  • Diastereomers typically have sufficiently distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) that they can be readily separated by taking advantage of these dissimilarities.
  • diastereomers can typically be separated by chromatography or by separation/resolution techniques based upon differences in solubility.
  • separation/resolution techniques A more detailed description of techniques that can be used to resolve stereoisomers of compounds from their raceric mixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley & Sons, Inc. (1981).
  • Compounds according to the present invention can also be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid.
  • a pharmaceutically acceptable base addition salt of a compound can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base.
  • Inorganic and organic acids and bases suitable for the preparation of the pharmaceutically acceptable salts of compounds are set forth in the defmitions section of this Application.
  • the salt forms of the compounds can be prepared using salts of the starting materials or intermediates.
  • the free acid or free base forms of the compounds can be prepared from the corresponding base addition salt or acid addition salt form.
  • a compound in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like).
  • a compound in a base addition salt form can be converted to the corresponding free acid by treating with a suitable acid (e.g., hydrochloric acid, etc).
  • N-oxides of compounds according to the present invention can be prepared by methods known to those of ordinary skill in the art.
  • N-oxides can be prepared by treating an unoxidized form of the compound with an oxidizing agent (e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like) in a suitable inert organic solvent (e.g., a halogenated hydrocarbon such as dichloromethane) at approximately 0° C.
  • an oxidizing agent e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like
  • a suitable inert organic solvent e.g., a halogenated hydrocarbon such as dichloromethane
  • the N-oxides of the compounds can be prepared from the N-oxide of an appropriate starting material.
  • Compounds in an unoxidized form can be prepared from N-oxides of compounds by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in an suitable inert organic solvent (e.g., acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 80° C.
  • a reducing agent e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like
  • an inert organic solvent e.g., acetonitrile, ethanol, aqueous dioxane, or the like
  • Prodrug derivatives of the compounds can be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et aL (1994), Bioorganic and Medicinal Chemistry Letters , Vol.4, p. 1985).
  • appropriate prodrugs can be prepared by reacting a non-derivatized compound with a suitable carbamylating agent (e.g., 1,1-acyloxyalkylcarbonochloridate, para-nitrophenyl carbonate, or the like).
  • Hydrates of compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.
  • Compounds according to the present invention can also be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomer. While resolution of enantiomers can be carried out using covalent diastereomeric derivatives of compounds, dissociable complexes are preferred (e.g., crystalline diastereoisomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilarities.
  • the diastereomers can be separated by chromatography or, preferably, by separation/resolution techniques based upon differences in solubility.
  • the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization.
  • a more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley & Sons, Inc. (1981).
  • g grams
  • mg milligrams
  • L liters
  • mL milliliters
  • ⁇ L microliters
  • psi pounds per square inch
  • M molar
  • mM millimolar
  • DPP-IV inhibitors according to the present invention may be synthesized according to a variety of reaction schemes. Some illustrative schemes are provided herein in the examples. Other reaction schemes could be readily devised by those skilled in the art.
  • Example 9A and Example 9B were synthesized from 2,6-Dichloro-7H-purine by the method described in syntheses of Example 7A and 8A.
  • Example 9A and Example 9B were converted to Example 9C and Example 9D by the method used in the preparation of Example 1C.
US10/809,638 2003-03-25 2004-03-24 Dipeptidyl peptidase inhibitors Abandoned US20040242566A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/809,638 US20040242566A1 (en) 2003-03-25 2004-03-24 Dipeptidyl peptidase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45778503P 2003-03-25 2003-03-25
US10/809,638 US20040242566A1 (en) 2003-03-25 2004-03-24 Dipeptidyl peptidase inhibitors

Publications (1)

Publication Number Publication Date
US20040242566A1 true US20040242566A1 (en) 2004-12-02

Family

ID=33131718

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/809,638 Abandoned US20040242566A1 (en) 2003-03-25 2004-03-24 Dipeptidyl peptidase inhibitors
US10/809,637 Expired - Fee Related US7687625B2 (en) 2003-03-25 2004-03-24 Dipeptidyl peptidase inhibitors
US10/809,636 Abandoned US20040242568A1 (en) 2003-03-25 2004-03-24 Dipeptidyl peptidase inhibitors
US10/809,635 Expired - Fee Related US7550590B2 (en) 2003-03-25 2004-03-24 Dipeptidyl peptidase inhibitors

Family Applications After (3)

Application Number Title Priority Date Filing Date
US10/809,637 Expired - Fee Related US7687625B2 (en) 2003-03-25 2004-03-24 Dipeptidyl peptidase inhibitors
US10/809,636 Abandoned US20040242568A1 (en) 2003-03-25 2004-03-24 Dipeptidyl peptidase inhibitors
US10/809,635 Expired - Fee Related US7550590B2 (en) 2003-03-25 2004-03-24 Dipeptidyl peptidase inhibitors

Country Status (7)

Country Link
US (4) US20040242566A1 (US20040242566A1-20041202-C00153.png)
EP (1) EP1608317B1 (US20040242566A1-20041202-C00153.png)
JP (1) JP4887139B2 (US20040242566A1-20041202-C00153.png)
KR (1) KR20050122220A (US20040242566A1-20041202-C00153.png)
CN (1) CN1894234A (US20040242566A1-20041202-C00153.png)
CA (1) CA2518465A1 (US20040242566A1-20041202-C00153.png)
WO (1) WO2004087053A2 (US20040242566A1-20041202-C00153.png)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20080090845A1 (en) * 2006-08-23 2008-04-17 Neurogen Corporation Haloalkyl-substituted pyrimidinone derivatives
US20090069347A1 (en) * 2006-08-23 2009-03-12 Neurogen Corporation 2-phenoxy pyrimidinone analogues
US20090257979A1 (en) * 2008-04-15 2009-10-15 Intermune, Inc. Novel Inhibitors of Hepatitis C Virus Replication
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7687625B2 (en) 2003-03-25 2010-03-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7723344B2 (en) 2003-08-13 2010-05-25 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7781584B2 (en) 2004-03-15 2010-08-24 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7825242B2 (en) 2004-07-16 2010-11-02 Takeda Pharmaceutical Company Limted Dipeptidyl peptidase inhibitors
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20110110890A1 (en) * 2009-11-09 2011-05-12 Intermune, Inc. Novel Inhibitors of Hepatitis C Virus Replication
US7960384B2 (en) 2006-03-28 2011-06-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US10555929B2 (en) 2015-03-09 2020-02-11 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1911754B1 (en) * 2003-08-13 2013-10-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AR051596A1 (es) * 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
JP2008520744A (ja) 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
AU2011201488B2 (en) * 2004-11-29 2011-11-17 Merck Sharp & Dohme Corp. Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
EP2390264A1 (en) 2005-02-11 2011-11-30 Amylin Pharmaceuticals Inc. GIP analog and hybrid polypeptides with selectable propperties
WO2007022946A1 (de) 2005-08-21 2007-03-01 Abbott Gmbh & Co. Kg Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
ATE549926T1 (de) 2005-08-26 2012-04-15 Merck Sharp & Dohme Kondensierte aminopiperidine als dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes
BRPI0616077B8 (pt) † 2005-09-14 2021-05-25 Takeda Pharmaceuticals Co composição farmacêutica formulada em uma dose única, kit, artigo de manufatura, uso da composição farmacêutica e uso de um ou mais compostos antidiabéticos
AU2006327069A1 (en) * 2005-12-23 2007-06-28 Novartis Ag Condensed heterocyclic compounds useful as DPP-IV inhibitors
EP1999108A1 (en) * 2006-03-28 2008-12-10 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
GB2453058A (en) 2006-04-04 2009-03-25 Univ California Kinase antagonists
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
KR20090004950A (ko) 2006-04-12 2009-01-12 프로비오드룩 아게 효소 억제제
KR101129868B1 (ko) 2006-10-04 2012-04-12 화이자 프로덕츠 인코포레이티드 칼슘 수용체 길항제로서의 피리도［4,3-ｄ］피리미딘-4(3Ｈ)-온 유도체
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
KR20120030570A (ko) 2007-04-03 2012-03-28 미쓰비시 타나베 파마 코퍼레이션 디펩티딜 펩티다아제 4 저해 화합물과 감미료와의 병용
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
SI2152712T1 (sl) 2007-05-11 2012-03-30 Pfizer Amino heterociklične spojine
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CN101965336B (zh) 2008-01-04 2015-06-17 英特利凯恩有限责任公司 某些化学实体、组合物和方法
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
US20100029371A1 (en) * 2008-08-01 2010-02-04 Gennady Medvinsky Personal Game Services Commerce System (PGSCS)
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
DK2358720T3 (en) 2008-10-16 2016-06-06 Univ California Heteroarylkinaseinhibitorer fused-ring
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
CN101817833B (zh) * 2009-02-26 2013-03-06 中国科学院广州生物医药与健康研究院 Dpp-iv抑制剂
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
ES2567168T3 (es) 2009-11-12 2016-04-20 F. Hoffmann-La Roche Ag Compuestos purina y pirazolopirimidina N7-sustituidos, composiciones y métodos de utilización
EA021568B1 (ru) 2009-12-23 2015-07-30 Такеда Фармасьютикал Компани Лимитед Конденсированные гетероароматические пирролидиноны как ингибиторы syk
US8648073B2 (en) 2009-12-30 2014-02-11 Fochon Pharma, Inc. Certain dipeptidyl peptidase inhibitors
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
CA2789440C (en) 2010-03-10 2020-03-24 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
CN102311448B (zh) * 2010-07-07 2014-02-19 中国科学院广州生物医药与健康研究院 噻吩并嘧啶酮类dpp-iv抑制剂
CN102311447B (zh) * 2010-07-07 2013-11-27 中国科学院广州生物医药与健康研究院 杂环并嘧啶酮类dpp-iv抑制剂
EA201390421A1 (ru) 2010-09-22 2013-09-30 Арена Фармасьютикалз, Инк. Модуляторы рецептора gpr119 и лечение связанных с ним нарушений
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
AR084824A1 (es) 2011-01-10 2013-06-26 Intellikine Inc Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
US8907086B2 (en) 2011-03-03 2014-12-09 Merck Sharp & Dohme Corp. Fused bicyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
JP6026525B2 (ja) 2011-06-22 2016-11-16 武田薬品工業株式会社 置換６−アザ−イソインドリン−１−オン誘導体
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6027611B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
BR112014003981A2 (pt) 2011-08-23 2017-03-07 Endo Pharmaceuticals Inc compostos de pirimido-piridazinona e seu uso
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN103130819B (zh) * 2011-12-01 2016-01-20 中国科学院上海药物研究所 噻吩[3,2-d]并嘧啶-4-酮类化合物、其制备方法、药物组合物及用途
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
NZ730134A (en) 2012-06-13 2018-07-27 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
AU2013323426A1 (en) 2012-09-26 2015-04-23 The Regents Of The University Of California Modulation of ire1
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN109912594A (zh) 2013-04-19 2019-06-21 因赛特控股公司 作为fgfr抑制剂的双环杂环
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
PL3052485T3 (pl) 2013-10-04 2022-02-28 Infinity Pharmaceuticals, Inc. Związki heterocykliczne i ich zastosowania
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160187724A1 (en) * 2013-10-08 2016-06-30 Sharp Kabushiki Kaisha Image display device
CA2943075C (en) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
KR101739003B1 (ko) * 2014-07-11 2017-05-23 에스티팜 주식회사 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
MX2018003058A (es) 2015-09-14 2018-08-01 Infinity Pharmaceuticals Inc Formas solidas de derivados de isoquinolinona, proceso de fabricacion, composiciones que las contienen y metodos de uso de las mismas.
KR101730790B1 (ko) 2015-12-24 2017-04-28 한국과학기술연구원 세로토닌 5-ｈｔ6 저해 활성을 갖는 5,6,7,8-테트라하이드로퀴나졸린-2-아민 화합물
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017223422A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
MA52494A (fr) 2018-05-04 2021-03-10 Incyte Corp Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation
CR20200591A (es) 2018-05-04 2021-03-31 Incyte Corp Sales de un inhibidor de fgfr
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022007163A2 (pt) 2019-10-14 2022-08-23 Incyte Corp Heterociclos bicíclicos como inibidores de fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021127071A1 (en) * 2019-12-18 2021-06-24 Merck Sharp & Dohme Corp. Bicyclic heterocycle compounds methods of use thereof for the treatment of herpes viruses
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環

Citations (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3823135A (en) * 1972-12-26 1974-07-09 Shell Oil Co Pyrimidone herbicides
US3960949A (en) * 1971-04-02 1976-06-01 Schering Aktiengesellschaft 1,2-Biguanides
US4494978A (en) * 1976-12-30 1985-01-22 Chevron Research Company Herbicidal N-(N'-hydrocarbyloxycarbamylalkyl)-2,6-dialkyl-alpha-haloacetanilides
US4935493A (en) * 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
US5387512A (en) * 1991-06-07 1995-02-07 Merck & Co. Inc. Preparation of 3-[z-benzoxazol-2-yl)ethyl]-5-(1-hydroxyethyl)-6-methyl-2-(1H)-pyridinone by biotransformation
US5433955A (en) * 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5614379A (en) * 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
US5624894A (en) * 1992-09-17 1997-04-29 University Of Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6090786A (en) * 1994-06-10 2000-07-18 Fondatech Benelux N.V. Serine proteases, their activity and their synthetic inhibitors
US6172081B1 (en) * 1999-06-24 2001-01-09 Novartis Ag Tetrahydroisoquinoline 3-carboxamide derivatives
US6184020B1 (en) * 1997-12-16 2001-02-06 Novo Nordisk Biotech, Inc. Polypeptides having aminopeptidase activity and nucleic acids encoding same
US6201132B1 (en) * 1993-12-03 2001-03-13 Ferring B.V. Inhibitors of DP-mediated processes, compositions, and therapeutic methods thereof
US6214340B1 (en) * 1997-11-18 2001-04-10 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Physiologically active substance sulphostin, process for producing the same, and use thereof
US6235493B1 (en) * 1997-08-06 2001-05-22 The Regents Of The University Of California Amino acid substituted-cresyl violet, synthetic fluorogenic substrates for the analysis of agents in individual in vivo cells or tissue
US6251391B1 (en) * 1999-10-01 2001-06-26 Klaire Laboratories, Inc. Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons
US6258597B1 (en) * 1997-09-29 2001-07-10 Point Therapeutics, Inc. Stimulation of hematopoietic cells in vitro
US6261794B1 (en) * 1999-10-14 2001-07-17 Saint Louis University Methods for identifying inhibitors of methionine aminopeptidases
US6265551B1 (en) * 1995-06-01 2001-07-24 Dana-Farber Cancer Institute, Inc. Form of dipeptidylpeptidase IV (CD26) found in human serum, antibodies thereto, and uses thereof
US20020006899A1 (en) * 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
US20020019411A1 (en) * 2000-03-10 2002-02-14 Robl Jeffrey A. Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6355614B1 (en) * 1998-06-05 2002-03-12 Point Therapeutics Cyclic boroproline compounds
US20020037829A1 (en) * 2000-08-23 2002-03-28 Aronson Peter S. Use of DPPIV inhibitors as diuretic and anti-hypertensive agents
US20020041871A1 (en) * 2000-06-01 2002-04-11 Brudnak Mark A. Genomeceutical and/or enzymatic composition and method for treating autism
US20020049153A1 (en) * 1999-05-17 2002-04-25 BRIDON Dominique P. Long lasting insulinoptropic peptides
US20020049164A1 (en) * 1998-06-24 2002-04-25 Hans-Ulrich Demuth Prodrugs of DP IV-inhibitors
US6380398B2 (en) * 2000-01-04 2002-04-30 Novo Nordisk A/S Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
US20020061839A1 (en) * 1998-03-09 2002-05-23 Scharpe Simon Lodewijk Serine peptidase modulators
US20020071838A1 (en) * 1998-07-31 2002-06-13 Hans-Ulrich Demuth Method for raising the blood glucose level in mammals
US20020077340A1 (en) * 2000-11-20 2002-06-20 Richard Sulsky Pyridone inhibitors of fatty acid binding protein and method
US20020082427A1 (en) * 1999-06-10 2002-06-27 Hans-Ulrich Demuth Method for the production of thiazolidin
US20020082292A1 (en) * 2000-09-27 2002-06-27 Sahoo Soumya P. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
US20030008905A1 (en) * 2000-03-31 2003-01-09 Hans-Ulrich Demuth Method for the improvement of islet signaling in diabetes mellitus and for its prevention
US20030008925A1 (en) * 1997-11-19 2003-01-09 Marc Esteve Treatment of drug-induced sleepiness
US20030027282A1 (en) * 1997-10-06 2003-02-06 Huber Brigitte T. Quiescent cell dipeptidyl peptidase: a novel cytoplasmic serine protease
US20030040478A1 (en) * 1999-12-08 2003-02-27 Drucker Daniel J Chemotherapy treatment
US20030045464A1 (en) * 1997-12-16 2003-03-06 Hermeling Ronald Norbert Glucagon-like peptide-1 crystals
US20030055052A1 (en) * 2000-11-10 2003-03-20 Stefan Peters FAP-activated anti-tumor compounds
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030060412A1 (en) * 2000-01-27 2003-03-27 Prouty Walter Francis Process for solubilizing glucagon-like peptide 1compounds
US20030069234A1 (en) * 2001-06-06 2003-04-10 Medina Julio C. CXCR3 antagonists
US6548481B1 (en) * 1998-05-28 2003-04-15 Probiodrug Ag Effectors of dipeptidyl peptidase IV
US20030087935A1 (en) * 1999-09-22 2003-05-08 Cheng Peter T. Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US20030087950A1 (en) * 2001-03-28 2003-05-08 Denanteuil Guillaume New alpha-amino acid sulphonyl compounds
US20030089935A1 (en) * 2001-11-13 2003-05-15 Macronix International Co., Ltd. Non-volatile semiconductor memory device with multi-layer gate insulating structure
US20030092630A2 (en) * 1999-08-24 2003-05-15 Probiodrug Ag New effectors of dipeptidyl peptidase iv for topical use
US20030092697A1 (en) * 2001-05-30 2003-05-15 Cheng Peter T. Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
US20030096857A1 (en) * 1999-11-30 2003-05-22 Evans David Michael Novel antidiabetic agents
US20030100563A1 (en) * 2001-07-06 2003-05-29 Edmondson Scott D. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20030105077A1 (en) * 2001-07-03 2003-06-05 Kanstrup Anders Bendtz Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
US20030103968A1 (en) * 2001-04-12 2003-06-05 Andree Amelsberg Use of alpha specific antibody BIBH1 in the treatment of cancer
US20030119750A1 (en) * 2001-06-27 2003-06-26 Hans-Ulrich Demuth Use of dipeptidyl peptidase IV inhibitors
US20030119736A1 (en) * 2001-04-02 2003-06-26 Hans-Ulrich Demuth Methods for improving islet signaling in diabetes mellitus and for its prevention
US20030119738A1 (en) * 2001-09-06 2003-06-26 Andre Niestroj Novel inhibitors of dipeptidyl peptidase I
US20030125304A1 (en) * 2001-11-09 2003-07-03 Hans-Ulrich Demuth Substituted amino ketone compounds
US20030130306A1 (en) * 2001-11-06 2003-07-10 Pratik Devasthale Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US20030130199A1 (en) * 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US20030130281A1 (en) * 2001-10-26 2003-07-10 Markus Boehringer DPP IV inhibitors
US20030135023A1 (en) * 2001-06-27 2003-07-17 Hans-Ulrich Demuth Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis
US20030139429A1 (en) * 2001-09-27 2003-07-24 Cohen David Saul Combinations
US20030139434A1 (en) * 2000-01-21 2003-07-24 Bork Balkan Combinations comprising dipeptidylpeptidase-iv inhibitor
US20030144206A1 (en) * 2001-12-29 2003-07-31 Knudsen Lotte Bjerre Combined use of a GLP-1 compound and modulator of diabetic late complications
US6673829B2 (en) * 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
US6686337B2 (en) * 2000-10-30 2004-02-03 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising anti-diabetic and anticonvulsant agents
US6706742B2 (en) * 2001-05-15 2004-03-16 Les Laboratories Servier Alpha-amino-acid compounds
US20040054171A1 (en) * 2002-07-04 2004-03-18 Jensen Anette Frost Polymorphic forms of a 4H-thieno[3,2-E]-1,2,4-thiadiazine 1,1-dioxide derivative
US6710040B1 (en) * 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
US6710843B2 (en) * 2001-06-19 2004-03-23 Samsung Electronics Co., Ltd. In-line system and method for manufacturing liquid crystal display
US20040058876A1 (en) * 2002-09-18 2004-03-25 Torsten Hoffmann Secondary binding site of dipeptidyl peptidase IV (DP IV)
US6727261B2 (en) * 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
US6747035B2 (en) * 2001-08-13 2004-06-08 Warner-Lambert Llc 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
US20040110817A1 (en) * 2002-11-18 2004-06-10 Pfizer Inc Dipeptidyl peptidase IV inhibiting fluorinated cyclic amides
US20040116328A1 (en) * 2002-06-06 2004-06-17 Eisai Co., Ltd. Condensed imidazole derivatives
US20040132732A1 (en) * 2002-10-21 2004-07-08 Wei Han Quinazolinones and derivatives thereof as factor Xa inhibitors
US20040138148A1 (en) * 2001-02-14 2004-07-15 Nobuhiko Fushimi Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
US20050014732A1 (en) * 2003-03-14 2005-01-20 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-diabetic agent
US20050020574A1 (en) * 2002-12-03 2005-01-27 Boehringer Ingelheim Pharma Gmbh Co. Kg New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
US20050026921A1 (en) * 2003-06-18 2005-02-03 Boehringer Ingelheim International Gmbh New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
US20050032804A1 (en) * 2003-06-24 2005-02-10 Cypes Stephen Howard Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
US20050038020A1 (en) * 2003-08-01 2005-02-17 Hamann Lawrence G. Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US20050043292A1 (en) * 2003-08-20 2005-02-24 Pfizer Inc Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors
US20050043299A1 (en) * 2001-10-23 2005-02-24 Ferring B. V. Inhibitors of dipeptidyl peptidase iv
US6867205B2 (en) * 2002-02-13 2005-03-15 Hoffman-La Roche Inc. Pyridine and pyrimidine derivatives
US20050058635A1 (en) * 2003-05-05 2005-03-17 Hans-Ulrich Demuth Use of effectors of glutaminyl and glutamate cyclases

Family Cites Families (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US150343A (en) * 1874-04-28 Ezra milleb
US114141A (en) * 1871-04-25 Improvement in steam-traps
US150344A (en) * 1874-04-28 Improvement in fluid-meters
US150353A (en) * 1874-04-28 Improvement in bearing-bars for furnace-grates
CH317122A (de) * 1952-09-03 1956-11-15 Basf Ag Verfahren zur Herstellung von Küpenfarbstoffen
DE1249281B (US20040242566A1-20041202-C00153.png) * 1963-05-18
DE1670912C3 (de) 1967-08-18 1981-06-11 Bayer Ag, 5090 Leverkusen Herbizide Mittel auf Basis von 1,2,4-Triazin-5-onen
GB1377642A (en) * 1971-01-14 1974-12-18 Koninklijke Gist Spiritus Penicillanic and cephalosporanic acid derivatives
DE2150686A1 (de) 1971-10-12 1973-04-19 Basf Ag 6-amino-uracil-5-carbonsaeurethioamide
AU5996573A (en) 1972-09-11 1975-03-06 Commonwealth Scientific And Industrial Research Organisation Pyridinium salts
GB1464248A (en) 1973-11-01 1977-02-09 Ici Ltd Substituted triazinediones their preparation and use as herbicides
DE2361551A1 (de) 1973-12-11 1975-06-19 Basf Ag Wasserloesliche azofarbstoffe
DE2500024A1 (de) 1975-01-02 1976-07-08 Basf Ag Wasserloesliche azofarbstoffe
JPS535180A (en) 1976-07-01 1978-01-18 Sumitomo Chem Co Ltd Preparation of 3,4-dihydro-2 (1h) quinazoline derivatives
DE2720085A1 (de) 1977-05-05 1978-11-16 Hoechst Ag Pyrimido(6,1-a)isochinolin-2-on- derivate
CH657851A5 (de) * 1983-06-28 1986-09-30 Ciba Geigy Ag Chromogene chinazolonverbindungen.
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
EP0842925A1 (en) 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
GB8900382D0 (en) 1989-01-09 1989-03-08 Janssen Pharmaceutica Nv 2-aminopyrimidinone derivatives
IE63502B1 (en) 1989-04-21 1995-05-03 Zeneca Ltd Aminopyrimidine derivatives useful for treating cardiovascular disorders
US5366862A (en) 1990-02-14 1994-11-22 Receptor Laboratories, Inc. Method for generating and screening useful peptides
US5814460A (en) 1990-02-14 1998-09-29 Diatide, Inc. Method for generating and screening useful peptides
ATE169915T1 (de) 1990-02-15 1998-09-15 Takeda Chemical Industries Ltd Pyrimidindionderivate, deren herstellung und verwendung
US5462928A (en) 1990-04-14 1995-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type IV
DE4110019C2 (de) 1991-03-27 2000-04-13 Merck Patent Gmbh Imidazopyridine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
EP0610317B1 (en) 1991-10-22 2001-01-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type iv
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
US5350752A (en) 1991-12-16 1994-09-27 E. R. Squibb & Sons, Inc. Dihydropyrimidine derivatives
DE4141788A1 (de) 1991-12-18 1993-06-24 Merck Patent Gmbh Imidazopyridine
EP0626964A1 (en) * 1992-02-19 1994-12-07 Pfizer Inc. Heterocyclic compounds for enhancing antitumor activity
DE4305602A1 (de) 1992-06-17 1993-12-23 Merck Patent Gmbh Imidazopyridine
EP0915090A1 (en) 1992-09-10 1999-05-12 Eli Lilly And Company Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
US5811281A (en) 1993-07-12 1998-09-22 Cornell Research Foundation, Inc. Immortalized intestinal epithelial cell lines
DE4341453A1 (de) 1993-12-06 1995-06-08 Merck Patent Gmbh Imidazopyridine
CN1066739C (zh) 1994-03-08 2001-06-06 株式会社大塚制药工场 膦酸二酯衍生物
US5580979A (en) 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US5543396A (en) 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
US5601986A (en) * 1994-07-14 1997-02-11 Amgen Inc. Assays and devices for the detection of extrahepatic biliary atresia
DE4432860A1 (de) 1994-09-15 1996-03-21 Merck Patent Gmbh Imidazopyridine
US5864468A (en) * 1995-01-13 1999-01-26 Methode Electronics, Inc. Removable optoelectronic module with grounding means
US5879173A (en) * 1995-01-13 1999-03-09 Methode Electronics, Inc. Removable transceiver module and receptacle
US5717533A (en) * 1995-01-13 1998-02-10 Methode Electronics Inc. Removable optoelectronic module
US5734558A (en) * 1995-01-13 1998-03-31 Poplawski; Daniel S. Removable optoelectronic module
US6325989B1 (en) 1995-06-01 2001-12-04 Dana-Farber Cancer Institute, Inc. Form of dipeptidylpeptidase IV (CD26) found in human serum
ATE201016T1 (de) 1995-06-09 2001-05-15 Hoffmann La Roche Pyrimidindion-, pyrimidintrion-, triazindion- derivate als alpha-1-adrenergische rezeptorantagonisten
JPH0928376A (ja) 1995-07-21 1997-02-04 Ajinomoto Co Inc 新規ジペプチジルペプチダーゼｉｖとその製造方法
TW445263B (en) * 1996-02-29 2001-07-11 Janssen Pharmaceutica Nv Novel esters of 1,4-disubstituted piperidine derivatives
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
US5965532A (en) 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
CA2258949C (en) 1996-07-01 2008-05-06 Dr. Reddy's Research Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
JP3468007B2 (ja) * 1997-02-05 2003-11-17 住友電装株式会社 レバー式コネクタ
US6100234A (en) 1997-05-07 2000-08-08 Tufts University Treatment of HIV
DE69840230D1 (de) 1997-05-16 2009-01-02 Novozymes Inc Polypeptide mit prolyldipeptidylaminopeptidase-aktivität und dafür kodierende nukleinsäuren
EP0897012A1 (en) 1997-07-05 1999-02-17 Societe Des Produits Nestle S.A. Cloning of the prolyl-dipeptidyl-peptidase from aspergillus oryzae
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US6342611B1 (en) * 1997-10-10 2002-01-29 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
EP1052994A2 (en) 1998-02-02 2000-11-22 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
US6129911A (en) 1998-07-10 2000-10-10 Rhode Island Hospital, A Lifespan Partner Liver stem cell
DE19844693A1 (de) * 1998-09-29 2000-03-30 Delphi Automotive Systems Gmbh Zweiteiliger elektrischer Verbinder
US20030176357A1 (en) 1998-10-06 2003-09-18 Pospisilik Andrew J. Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
GB9906715D0 (en) * 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
AU3958100A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
US6107317A (en) 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6617340B1 (en) 1999-07-29 2003-09-09 Novartis Ag N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
WO2001016114A2 (en) * 1999-08-27 2001-03-08 Chemocentryx, Inc. Heterocyclic compounds and methods for modulating cxcr3 function
ES2234662T3 (es) * 1999-09-16 2005-07-01 Curis, Inc. Mediadores de rutas de señalizacion hedgehog, composiciones y usos relacionados con los mismos.
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
WO2001023364A1 (en) 1999-09-28 2001-04-05 Merck Patent Gmbh Quinazolinones
US6447772B1 (en) 1999-10-01 2002-09-10 Klaire Laboratories, Inc. Compositions and methods relating to reduction of symptoms of autism
JP2001172257A (ja) * 1999-10-05 2001-06-26 Fujisawa Pharmaceut Co Ltd 有機スルホンアミド化合物
WO2001027090A1 (en) 1999-10-08 2001-04-19 Meiji Seika Kaisha, Ltd. m-SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING INTEGRINαvβ3 ANTAGONISM
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
KR20050049562A (ko) * 1999-10-27 2005-05-25 싸이토키네틱스, 인코포레이티드 퀴나졸리논을 사용하는 방법 및 조성물
US20040152745A1 (en) 1999-11-12 2004-08-05 Guilford Pharmaceuticals, Inc. Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
CA2390231A1 (en) 1999-11-12 2001-05-17 Paul Jackson Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
US6517382B2 (en) * 1999-12-01 2003-02-11 Tyco Electronics Corporation Pluggable module and receptacle
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
US6448045B1 (en) 2000-03-10 2002-09-10 The Regents Of The University Of California Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1
US6608038B2 (en) 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
EP1136482A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6545170B2 (en) * 2000-04-13 2003-04-08 Pharmacia Corporation 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
ES2567260T3 (es) * 2000-04-25 2016-04-21 Icos Corporation Inhibidores de la fosfatidilinositol 3-quinasa delta humana
GB0010183D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0010188D0 (en) * 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
TW583185B (en) 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
US6432969B1 (en) 2000-06-13 2002-08-13 Novartis Ag N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6627636B2 (en) 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US6620821B2 (en) 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
MXPA02012272A (es) * 2000-07-04 2003-04-25 Novo Nordisk As Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
JP2002042960A (ja) * 2000-07-25 2002-02-08 Yazaki Corp コネクタ支持機構
AU2001281083A1 (en) 2000-08-01 2002-02-13 Pharmacia Corporation Hexahydro-7-1h-azepin-2-yl-haxanoic acid derivatives as inhibitors of inducible nitric oxide synthase
US7022711B2 (en) 2000-08-04 2006-04-04 Warner-Lambert Company 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimidin-7-ones
JP4101053B2 (ja) 2000-08-10 2008-06-11 田辺三菱製薬株式会社 プロリン誘導体及びその医薬用途
US20020165237A1 (en) 2000-08-11 2002-11-07 Fryburg David Albert Treatment of the insulin resistance syndrome
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
US20020064736A1 (en) * 2000-09-27 2002-05-30 Fuji Photo Film Co., Ltd. Dye-forming coupler, silver halide photographic light-sensitive material, and method for producing an azomethine dye
IL154893A0 (en) * 2000-10-06 2003-10-31 Tanabe Seiyaku Co Aliphatic nitrogen-containing cyclic compounds, methods for the preparation thereof and pharmaceutical compositions containing the same
RU2305133C2 (ru) 2000-10-12 2007-08-27 Ферринг Бв Ген новой сериновой протеазы, родственной dppiv
AUPR107800A0 (en) * 2000-10-27 2000-11-23 University Of Sydney, The Peptide and nucleic acid molecule ii
JP2004512300A (ja) 2000-10-27 2004-04-22 プロバイオドラッグ　アーゲー 神経学的および神経心理学的疾患の治療方法
CA2427610A1 (en) 2000-10-31 2002-08-08 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
WO2002059343A2 (en) 2000-10-31 2002-08-01 Vanderbilt University Biological markers and diagnostic tests for angiotensin converting enzyme inhibitor- and vasopeptidase inhibitor-associated angioedema
US6864363B2 (en) 2000-11-08 2005-03-08 University Of Georgia Research Foundation, Inc. Dipeptidylpeptidases and methods of use
US20020155565A1 (en) 2000-11-10 2002-10-24 Pilar Garin-Chesa FAP-activated anti-tumor compounds
TWI243162B (en) * 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
NZ526622A (en) 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
JPWO2002051836A1 (ja) 2000-12-27 2004-04-22 協和醗酵工業株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
DE10100053A1 (de) 2001-01-02 2002-08-22 Keyneurotek Ag I G Verwendung von Enzyminhibitoren der Dipeptidylpeptidase IV sowie der Aminopeptidase N und pharmazeutischen Zubereitungen daraus zur Prävention und/oder Therapie Ischämie-bedingter akuter und chronischer neurodegenerativer Prozesse und Erkrankungen
BR0206831A (pt) * 2001-02-02 2004-07-06 Takeda Chemical Industries Ltd Composto, cristal, agente farmacêutico, agentes para profilaxia ou tratamento de diabetes, de complicações diabéticas, de tolerância prejudicada à glucose e de obesidade, inibidor de peptidase, uso de um composto, e, método de produção de um composto
WO2002062798A2 (en) * 2001-02-05 2002-08-15 Dr. Reddy's Laboratories Ltd. Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
CZ301487B6 (cs) * 2001-02-24 2010-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthinové deriváty, jejich výroba a použití jako lécivo
US6337069B1 (en) 2001-02-28 2002-01-08 B.M.R.A. Corporation B.V. Method of treating rhinitis or sinusitis by intranasally administering a peptidase
US6371787B1 (en) * 2001-03-07 2002-04-16 International Business Machines Corporation Pull-to-release type latch mechanism for removable small form factor electronic modules
PT1372650E (pt) * 2001-03-19 2009-02-25 Novartis Ag Associações compreendendo um agente antidiarreico e uma epotilona ou um derivado de epotilona
US7026316B2 (en) 2001-03-27 2006-04-11 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
DE10115921A1 (de) 2001-03-30 2002-10-02 Boehringer Ingelheim Pharma Verfahren zur Herstellung von 4,6-Diaminopyrimido[5,4-d]pyrimidinen
GB0109146D0 (en) 2001-04-11 2001-05-30 Ferring Bv Treatment of type 2 diabetes
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
US20030060494A1 (en) 2001-05-18 2003-03-27 Nobuyuki Yasuda Pharmaceutical use of N-carbamoylazole derivatives
JP2004535433A (ja) 2001-06-20 2004-11-25 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療用のジペプチジルペプチダーゼ阻害薬
ATE318139T1 (de) 2001-06-20 2006-03-15 Merck & Co Inc Dipeptidylpeptidase-hemmer zur behandlung von diabetes
ES2296962T3 (es) 2001-06-27 2008-05-01 Smithkline Beecham Corporation Pirrolidinas como inhibidores de dipeptidil peptidasa.
US7183290B2 (en) 2001-06-27 2007-02-27 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
DE10150203A1 (de) 2001-10-12 2003-04-17 Probiodrug Ag Peptidylketone als Inhibitoren der DPIV
WO2003002593A2 (en) 2001-06-27 2003-01-09 Probiodrug Ag Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis
EP1406873B1 (en) 2001-06-27 2007-09-26 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
CA2418543A1 (en) 2001-06-27 2003-01-09 Probiodrug Ag New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
US20030144350A1 (en) 2001-07-20 2003-07-31 Adipogenix, Inc. Fat accumulation-modulation compounds
WO2003016335A2 (en) 2001-08-13 2003-02-27 Probiodrug Ag Irreversible cysteine protease inhibitors of legumain
DE10143840A1 (de) 2001-09-06 2003-03-27 Probiodrug Ag Neue Inhibitoren der Dipeptidylpeptidase I
CA2460512A1 (en) 2001-09-14 2003-03-27 Mitsubishi Pharma Corporation Thiazolidine derivatives and medicinal use thereof
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
AU2002331311A1 (en) 2001-09-19 2003-04-01 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
EA007224B1 (ru) 2001-09-21 2006-08-25 Мицубиси Фарма Корпорейшн Производные 3-замещенных 4-пиримидонов
NZ531636A (en) 2001-09-21 2005-11-25 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives as tau protein kinase 1 inhibitor
SI1427415T1 (sl) 2001-09-21 2009-12-31 Bristol Myers Squibb Co Sestavine, ki vsebujejo laktame in njihovi derivati kot inhibitorji faktorja xa
MXPA04002993A (es) * 2001-10-01 2004-07-15 Bristol Myers Squibb Co Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios.
WO2003030946A1 (en) 2001-10-09 2003-04-17 Novartis Ag Regulation of insulin production
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
TWI301834B (en) 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
WO2003039460A2 (en) * 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
IL161717A0 (en) 2001-11-26 2004-09-27 Schering Corp Piperidine-based mch antagonists for treatment of obesity and cns disorders
EP2769715A3 (en) 2001-11-26 2014-09-17 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
EP1469873A4 (en) 2001-11-26 2007-10-03 Tufts College PEPTIDOMIMETIC INHIBITORS OF POST-PROLINE CLEAVAGE ENZYMES
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
DE60222302T2 (de) * 2001-12-06 2008-05-29 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
CZ2004714A3 (cs) 2001-12-14 2004-10-13 Novoánordiskáa@S Sloučeniny a jejich použití ke snížení aktivity lipázy citlivé vůči hormonu
JP2005518391A (ja) 2001-12-21 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ Ｇｋ活性化剤としてのアミド誘導体
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
ATE409466T1 (de) 2002-01-11 2008-10-15 Novo Nordisk As Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen
WO2003063903A2 (en) 2002-02-01 2003-08-07 Probiodrug Ag Modulation of t lymphocytes using dp iv inhibitors
US7101898B2 (en) 2002-02-01 2006-09-05 Novo Nordisk A/S Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
MXPA04007743A (es) 2002-02-13 2004-10-15 Hoffmann La Roche Nuevos derivados de piridina y quinolina.
EA200400980A1 (ru) 2002-02-27 2005-02-24 Пфайзер Продактс Инк. Ингибиторы асс
ATE349435T1 (de) 2002-02-28 2007-01-15 Prosidion Ltd Dpiv-inhibitoren auf glutaminbasis
US20080070864A1 (en) 2002-03-07 2008-03-20 X-Ceptor Therapeutics, Inc. Quinazolinone Modulators Of Nuclear Receptors
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
EP1492777A1 (en) 2002-04-08 2005-01-05 Torrent Pharmaceuticals Ltd Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidase inhibitors
US20040106802A1 (en) * 2002-04-08 2004-06-03 Torrent Pharmaceuticals Ltd. Novel compounds and therapeutic uses thereof
JP2003300977A (ja) 2002-04-10 2003-10-21 Sumitomo Pharmaceut Co Ltd キサンチン誘導体
EP2204181A3 (en) 2002-04-30 2010-09-22 Trustees Of Tufts College Protease inhibitors
TW200307667A (en) * 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
MXPA04011557A (es) 2002-05-23 2005-07-05 Chiron Corp Compuestos de quinazolinona sustituida.
GB0212412D0 (en) 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
AU2003233010A1 (en) 2002-06-04 2003-12-19 Pfizer Products Inc. Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
WO2003106628A2 (en) * 2002-06-17 2003-12-24 Bristol-Myers Squibb Company Benzodiazepine inhibitors of mitochondial f1f0 atp hydrolase and methods of inhibiting f1f0 atp hydrolase
CA2489648A1 (en) 2002-06-17 2003-12-24 Smithkline Beecham Corporation Chemical process
SE0201976D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
AU2002331226A1 (en) 2002-08-09 2004-03-11 Prosidion Ltd. Methods for improving islet signaling in diabetes mellitus and for its prevention
AU2003262747A1 (en) * 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10238477A1 (de) * 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US6998502B1 (en) 2002-09-05 2006-02-14 Sabinsa Corporation Convenient process of manufacture for difluoromethylornithine and related compounds
EP1398032A1 (en) 2002-09-10 2004-03-17 PheneX Pharmaceuticals AG 4-Oxo-quinazolines as LXR nuclear receptor binding compounds
EP1407774A1 (en) * 2002-09-10 2004-04-14 LION Bioscience AG 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
JP2004123738A (ja) 2002-09-11 2004-04-22 Takeda Chem Ind Ltd 徐放性製剤
EP1543023B1 (en) 2002-09-18 2010-03-17 Prosidion Limited Secondary binding site of dipeptidyl peptidase iv (dp iv)
US7262207B2 (en) 2002-09-19 2007-08-28 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US6869966B2 (en) * 2002-09-30 2005-03-22 Banyu Pharmaceutical Co., Ltd. N-substituted-2-oxodihydropyridine derivatives
DE60320008T2 (de) 2002-10-18 2009-06-18 Merck & Co., Inc. Heterozyklische beta-aminoverbindungen als inhibitoren des dipeptidylpeptidase zur behandlung bzw. prevention von diabetes
DE60332856D1 (de) 2002-10-23 2010-07-15 Bristol Myers Squibb Co Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10256264A1 (de) 2002-12-03 2004-06-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Imidazo-pyridinone und Imidazo-pyridazinone, ihre Herstellung und ihre Verwendung als Arzneimittel
UY28103A1 (es) * 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
WO2004062613A2 (en) 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
WO2004078758A1 (en) * 2003-03-07 2004-09-16 Astrazeneca Ab Novel fused heterocycles and uses thereof
CA2518465A1 (en) 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
WO2004098591A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
US20040229848A1 (en) 2003-05-05 2004-11-18 Hans-Ulrich Demuth Glutaminyl based DP IV-inhibitors
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
NZ544221A (en) 2003-06-20 2009-05-31 Hoffmann La Roche Pyrido[2,1-a]-isoquinoline derivatives as DPP-IV inhibitors
MXPA05013734A (es) 2003-06-20 2006-03-08 Hoffmann La Roche Hexahidropiroisoquinolinas como inhibidores de dpp-iv.
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
JP2007513058A (ja) 2003-09-08 2007-05-24 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
AU2004293012A1 (en) * 2003-11-19 2005-06-09 Rustum S. Boyce Quinazolinone compounds with reduced bioaccumulation
US7304086B2 (en) 2004-02-05 2007-12-04 Probiodrug Ag Inhibitors of glutaminyl cyclase
CN102134231B (zh) 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors

Patent Citations (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960949A (en) * 1971-04-02 1976-06-01 Schering Aktiengesellschaft 1,2-Biguanides
US3823135A (en) * 1972-12-26 1974-07-09 Shell Oil Co Pyrimidone herbicides
US4494978A (en) * 1976-12-30 1985-01-22 Chevron Research Company Herbicidal N-(N'-hydrocarbyloxycarbamylalkyl)-2,6-dialkyl-alpha-haloacetanilides
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4935493A (en) * 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
US5433955A (en) * 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
US5387512A (en) * 1991-06-07 1995-02-07 Merck & Co. Inc. Preparation of 3-[z-benzoxazol-2-yl)ethyl]-5-(1-hydroxyethyl)-6-methyl-2-(1H)-pyridinone by biotransformation
US5624894A (en) * 1992-09-17 1997-04-29 University Of Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
US6201132B1 (en) * 1993-12-03 2001-03-13 Ferring B.V. Inhibitors of DP-mediated processes, compositions, and therapeutic methods thereof
US6090786A (en) * 1994-06-10 2000-07-18 Fondatech Benelux N.V. Serine proteases, their activity and their synthetic inhibitors
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5614379A (en) * 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
US6265551B1 (en) * 1995-06-01 2001-07-24 Dana-Farber Cancer Institute, Inc. Form of dipeptidylpeptidase IV (CD26) found in human serum, antibodies thereto, and uses thereof
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US6235493B1 (en) * 1997-08-06 2001-05-22 The Regents Of The University Of California Amino acid substituted-cresyl violet, synthetic fluorogenic substrates for the analysis of agents in individual in vivo cells or tissue
US6258597B1 (en) * 1997-09-29 2001-07-10 Point Therapeutics, Inc. Stimulation of hematopoietic cells in vitro
US6703238B2 (en) * 1997-09-29 2004-03-09 Point Therapeutics, Inc. Methods for expanding antigen-specific T cells
US20030027282A1 (en) * 1997-10-06 2003-02-06 Huber Brigitte T. Quiescent cell dipeptidyl peptidase: a novel cytoplasmic serine protease
US6214340B1 (en) * 1997-11-18 2001-04-10 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Physiologically active substance sulphostin, process for producing the same, and use thereof
US20030008925A1 (en) * 1997-11-19 2003-01-09 Marc Esteve Treatment of drug-induced sleepiness
US20030045464A1 (en) * 1997-12-16 2003-03-06 Hermeling Ronald Norbert Glucagon-like peptide-1 crystals
US6184020B1 (en) * 1997-12-16 2001-02-06 Novo Nordisk Biotech, Inc. Polypeptides having aminopeptidase activity and nucleic acids encoding same
US20020061839A1 (en) * 1998-03-09 2002-05-23 Scharpe Simon Lodewijk Serine peptidase modulators
US20030134802A1 (en) * 1998-05-28 2003-07-17 Hans-Ulrich Demuth Novel effectors of dipepetidyl peptidase IV
US6548481B1 (en) * 1998-05-28 2003-04-15 Probiodrug Ag Effectors of dipeptidyl peptidase IV
US6355614B1 (en) * 1998-06-05 2002-03-12 Point Therapeutics Cyclic boroproline compounds
US20020049164A1 (en) * 1998-06-24 2002-04-25 Hans-Ulrich Demuth Prodrugs of DP IV-inhibitors
US20020071838A1 (en) * 1998-07-31 2002-06-13 Hans-Ulrich Demuth Method for raising the blood glucose level in mammals
US20020006899A1 (en) * 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
US20020049153A1 (en) * 1999-05-17 2002-04-25 BRIDON Dominique P. Long lasting insulinoptropic peptides
US20020082427A1 (en) * 1999-06-10 2002-06-27 Hans-Ulrich Demuth Method for the production of thiazolidin
US6172081B1 (en) * 1999-06-24 2001-01-09 Novartis Ag Tetrahydroisoquinoline 3-carboxamide derivatives
US20030092630A2 (en) * 1999-08-24 2003-05-15 Probiodrug Ag New effectors of dipeptidyl peptidase iv for topical use
US6727271B2 (en) * 1999-09-22 2004-04-27 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US20030087935A1 (en) * 1999-09-22 2003-05-08 Cheng Peter T. Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US20030096846A1 (en) * 1999-09-22 2003-05-22 Cheng Peter T. Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6251391B1 (en) * 1999-10-01 2001-06-26 Klaire Laboratories, Inc. Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons
US6261794B1 (en) * 1999-10-14 2001-07-17 Saint Louis University Methods for identifying inhibitors of methionine aminopeptidases
US20030096857A1 (en) * 1999-11-30 2003-05-22 Evans David Michael Novel antidiabetic agents
US20030040478A1 (en) * 1999-12-08 2003-02-27 Drucker Daniel J Chemotherapy treatment
US6380398B2 (en) * 2000-01-04 2002-04-30 Novo Nordisk A/S Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
US20030139434A1 (en) * 2000-01-21 2003-07-24 Bork Balkan Combinations comprising dipeptidylpeptidase-iv inhibitor
US20030060412A1 (en) * 2000-01-27 2003-03-27 Prouty Walter Francis Process for solubilizing glucagon-like peptide 1compounds
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US20020019411A1 (en) * 2000-03-10 2002-02-14 Robl Jeffrey A. Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US20030008905A1 (en) * 2000-03-31 2003-01-09 Hans-Ulrich Demuth Method for the improvement of islet signaling in diabetes mellitus and for its prevention
US20020041871A1 (en) * 2000-06-01 2002-04-11 Brudnak Mark A. Genomeceutical and/or enzymatic composition and method for treating autism
US20020037829A1 (en) * 2000-08-23 2002-03-28 Aronson Peter S. Use of DPPIV inhibitors as diuretic and anti-hypertensive agents
US20020082292A1 (en) * 2000-09-27 2002-06-27 Sahoo Soumya P. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
US6686337B2 (en) * 2000-10-30 2004-02-03 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising anti-diabetic and anticonvulsant agents
US20030055052A1 (en) * 2000-11-10 2003-03-20 Stefan Peters FAP-activated anti-tumor compounds
US20020077340A1 (en) * 2000-11-20 2002-06-20 Richard Sulsky Pyridone inhibitors of fatty acid binding protein and method
US20040138148A1 (en) * 2001-02-14 2004-07-15 Nobuhiko Fushimi Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
US20030087950A1 (en) * 2001-03-28 2003-05-08 Denanteuil Guillaume New alpha-amino acid sulphonyl compounds
US6716843B2 (en) * 2001-03-28 2004-04-06 Les Laboratoires Servier Alpha-amino acid sulphonyl compounds
US20030119736A1 (en) * 2001-04-02 2003-06-26 Hans-Ulrich Demuth Methods for improving islet signaling in diabetes mellitus and for its prevention
US20030103968A1 (en) * 2001-04-12 2003-06-05 Andree Amelsberg Use of alpha specific antibody BIBH1 in the treatment of cancer
US6706742B2 (en) * 2001-05-15 2004-03-16 Les Laboratories Servier Alpha-amino-acid compounds
US20030092697A1 (en) * 2001-05-30 2003-05-15 Cheng Peter T. Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
US20030069234A1 (en) * 2001-06-06 2003-04-10 Medina Julio C. CXCR3 antagonists
US6710843B2 (en) * 2001-06-19 2004-03-23 Samsung Electronics Co., Ltd. In-line system and method for manufacturing liquid crystal display
US20030135023A1 (en) * 2001-06-27 2003-07-17 Hans-Ulrich Demuth Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis
US20030130199A1 (en) * 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US20030119750A1 (en) * 2001-06-27 2003-06-26 Hans-Ulrich Demuth Use of dipeptidyl peptidase IV inhibitors
US20030105077A1 (en) * 2001-07-03 2003-06-05 Kanstrup Anders Bendtz Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
US20030100563A1 (en) * 2001-07-06 2003-05-29 Edmondson Scott D. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US6699871B2 (en) * 2001-07-06 2004-03-02 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US6747035B2 (en) * 2001-08-13 2004-06-08 Warner-Lambert Llc 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
US20030119738A1 (en) * 2001-09-06 2003-06-26 Andre Niestroj Novel inhibitors of dipeptidyl peptidase I
US6673829B2 (en) * 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
US20030139429A1 (en) * 2001-09-27 2003-07-24 Cohen David Saul Combinations
US20050043299A1 (en) * 2001-10-23 2005-02-24 Ferring B. V. Inhibitors of dipeptidyl peptidase iv
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
US20030130281A1 (en) * 2001-10-26 2003-07-10 Markus Boehringer DPP IV inhibitors
US20030130306A1 (en) * 2001-11-06 2003-07-10 Pratik Devasthale Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6673815B2 (en) * 2001-11-06 2004-01-06 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US20050014946A1 (en) * 2001-11-09 2005-01-20 Hans-Ulrich Demuth Substituted amino ketone compounds
US20030125304A1 (en) * 2001-11-09 2003-07-03 Hans-Ulrich Demuth Substituted amino ketone compounds
US20030089935A1 (en) * 2001-11-13 2003-05-15 Macronix International Co., Ltd. Non-volatile semiconductor memory device with multi-layer gate insulating structure
US6727261B2 (en) * 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
US20030144206A1 (en) * 2001-12-29 2003-07-31 Knudsen Lotte Bjerre Combined use of a GLP-1 compound and modulator of diabetic late complications
US6867205B2 (en) * 2002-02-13 2005-03-15 Hoffman-La Roche Inc. Pyridine and pyrimidine derivatives
US20040132713A1 (en) * 2002-06-04 2004-07-08 Pfizer Inc Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
US6710040B1 (en) * 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
US20040116328A1 (en) * 2002-06-06 2004-06-17 Eisai Co., Ltd. Condensed imidazole derivatives
US20040054171A1 (en) * 2002-07-04 2004-03-18 Jensen Anette Frost Polymorphic forms of a 4H-thieno[3,2-E]-1,2,4-thiadiazine 1,1-dioxide derivative
US20040058876A1 (en) * 2002-09-18 2004-03-25 Torsten Hoffmann Secondary binding site of dipeptidyl peptidase IV (DP IV)
US20040132732A1 (en) * 2002-10-21 2004-07-08 Wei Han Quinazolinones and derivatives thereof as factor Xa inhibitors
US20040110817A1 (en) * 2002-11-18 2004-06-10 Pfizer Inc Dipeptidyl peptidase IV inhibiting fluorinated cyclic amides
US20050020574A1 (en) * 2002-12-03 2005-01-27 Boehringer Ingelheim Pharma Gmbh Co. Kg New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
US20050014732A1 (en) * 2003-03-14 2005-01-20 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-diabetic agent
US20050058635A1 (en) * 2003-05-05 2005-03-17 Hans-Ulrich Demuth Use of effectors of glutaminyl and glutamate cyclases
US20050026921A1 (en) * 2003-06-18 2005-02-03 Boehringer Ingelheim International Gmbh New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
US20050032804A1 (en) * 2003-06-24 2005-02-10 Cypes Stephen Howard Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
US20050038020A1 (en) * 2003-08-01 2005-02-17 Hamann Lawrence G. Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US20050043292A1 (en) * 2003-08-20 2005-02-24 Pfizer Inc Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687625B2 (en) 2003-03-25 2010-03-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7723344B2 (en) 2003-08-13 2010-05-25 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790736B2 (en) 2003-08-13 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8288539B2 (en) 2004-03-15 2012-10-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8173663B2 (en) 2004-03-15 2012-05-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7781584B2 (en) 2004-03-15 2010-08-24 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8329900B2 (en) 2004-03-15 2012-12-11 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8188275B2 (en) 2004-03-15 2012-05-29 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7807689B2 (en) 2004-03-15 2010-10-05 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7906523B2 (en) 2004-03-15 2011-03-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7825242B2 (en) 2004-07-16 2010-11-02 Takeda Pharmaceutical Company Limted Dipeptidyl peptidase inhibitors
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7960384B2 (en) 2006-03-28 2011-06-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8003656B2 (en) 2006-08-23 2011-08-23 Neurogen Corporation 2-phenoxy pyrimidinone analogues
US20090069347A1 (en) * 2006-08-23 2009-03-12 Neurogen Corporation 2-phenoxy pyrimidinone analogues
US20080090845A1 (en) * 2006-08-23 2008-04-17 Neurogen Corporation Haloalkyl-substituted pyrimidinone derivatives
US8759361B2 (en) 2006-08-23 2014-06-24 Neurogen Corporation 2-phenoxy pyrimidinone analogues
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US20090257979A1 (en) * 2008-04-15 2009-10-15 Intermune, Inc. Novel Inhibitors of Hepatitis C Virus Replication
US20110110890A1 (en) * 2009-11-09 2011-05-12 Intermune, Inc. Novel Inhibitors of Hepatitis C Virus Replication
US10555929B2 (en) 2015-03-09 2020-02-11 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US10772865B2 (en) 2015-03-09 2020-09-15 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11400072B2 (en) 2015-03-09 2022-08-02 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy

Also Published As

Publication number Publication date
US20040259870A1 (en) 2004-12-23
CN1894234A (zh) 2007-01-10
CA2518465A1 (en) 2004-10-14
KR20050122220A (ko) 2005-12-28
US20040242568A1 (en) 2004-12-02
EP1608317A2 (en) 2005-12-28
JP4887139B2 (ja) 2012-02-29
WO2004087053A3 (en) 2006-08-31
WO2004087053A9 (en) 2004-11-11
WO2004087053A2 (en) 2004-10-14
US7550590B2 (en) 2009-06-23
EP1608317B1 (en) 2012-09-26
US20050004117A1 (en) 2005-01-06
US7687625B2 (en) 2010-03-30
JP2007524600A (ja) 2007-08-30
EP1608317A4 (en) 2006-12-27

Similar Documents

Publication Publication Date Title
US7550590B2 (en) Dipeptidyl peptidase inhibitors
US7872124B2 (en) Dipeptidyl peptidase inhibitors
US7825242B2 (en) Dipeptidyl peptidase inhibitors
EP1506967B1 (en) Dipeptidyl peptidase inhibitors
US7960384B2 (en) Dipeptidyl peptidase inhibitors
EP1699777B1 (en) Dipeptidyl peptidase inhibitors
US20050250829A1 (en) Kinase inhibitors
WO2005095381A1 (en) Dipeptidyl peptidase inhibitors
US7550598B2 (en) Kinase inhibitors
EP1911754B1 (en) Dipeptidyl peptidase inhibitors

Legal Events

Date Code Title Description
AS Assignment

Owner name: SYNX, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FENG, JUN;GWALTNEY, STEPHEN L.;KALDOR, STEPHEN W.;AND OTHERS;REEL/FRAME:015654/0194;SIGNING DATES FROM 20040709 TO 20040802

AS Assignment

Owner name: QUALCOMM, INCORPORATED, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUTIVONG, ARAK;NAGUIB, AYMAN FAWAY;ARGAWAL, AVNEESH;REEL/FRAME:015069/0566;SIGNING DATES FROM 20040617 TO 20040630

AS Assignment

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED,JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TAKEDA SAN DIEGO, INC.;REEL/FRAME:017182/0232

Effective date: 20060111

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TAKEDA SAN DIEGO, INC.;REEL/FRAME:017182/0232

Effective date: 20060111

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION